UnitedHealth's (UNH.N) insurance unit said on Tuesday that a broad range of conditions will no longer need prior approval, effective October 1, as it aims to eliminate prior authorization for 30% of healthcare services by the end of this year.
Here are the details:
The reduction spans a broad mix of services across multiple clinical specialties, including cardiology, genetic and laboratory testing, chiropractic care, physical, occupational and speech therapy, orthopedic and musculoskeletal procedures, among others.
The prior authorization requirements are being eliminated across its commercial plans, Medicare Advantage for older adults and individual insurance under the Affordable Care Act, also known as Obamacare, and some other types of plans.
Health insurers have been taking measures to simplify their requirements for prior authorization on medicines and medical services after complaints from patients and doctors over excessive paperwork that can delay or even deny needed care.
The actions are designed to reduce unnecessary paperwork, make information easier to understand and allow patients and care providers more time to focus on care, UnitedHealthcare said.
The company is also reducing administrative requirements for eligible rural hospitals and affiliated providers through a rural prior authorization waiver program scheduled to begin on November 1.
UnitedHealthcare is speeding payments by up to 50% for about 1,400 rural hospitals and Critical Access Hospitals in the third quarter.
Novartis oznámil, že experimentální tableta remibrutinib uspěla v pozdních fázích klinického vývoje u roztroušené sklerózy a snížila relapsy i mozkové léze ve srovnání s teriflunomidem. Akcie v Curychu po zprávě vzrostly až o 5,6 %.
Farmaceutický gigant Novartis oznámil slibné výsledky pozdních klinických studií svého experimentálního léku remibrutinib určeného k léčbě roztroušené sklerózy (RS). Podle společnosti pacienti užívající tento přípravek vykazovali nižší počet relapsů onemocnění i menší rozsah mozkových lézí než nemocní léčení zavedeným přípravkem teriflunomid. Akcie kótované v Curychu reagovaly na zprávu růstem až o 5,6 procenta.
Podle Novartisu byl lék také efektivní v tom, že během studií nebyly zaznamenány známky jaterní toxicity, která bývá u některých podobných terapií sledovaným rizikem.
Úspěch remibrutinibu (ve formě pilulky) by mohl švýcarskému výrobci otevřít cestu k novému perorálnímu léku na roztroušenou sklerózu a současně rozšířit jeho portfolio navazující na úspěšnou značku Kesimpta.
Výsledky jsou zároveň důležitým signálem pro celou skupinu takzvaných BTK inhibitorů, tedy léků zaměřených na omezení nežádoucí aktivity imunitního systému. Některé konkurenční projekty vyvíjené společnostmi Sanofi a Merck KGaA totiž v pokročilých studiích nedokázaly prokázat lepší výsledky než již zavedený teriflunomid.
„Výsledky jsou dobrou zprávou pro pacienty i Novartis,“ řekl Bloombergu Stefan Schneider, analytik společnosti Vontobel a poukázal právě na trnitou historii inhibitorů BTK u roztroušené sklerózy. Na základě nových dat zároveň snížil rizikovou přirážku (z 50 % na 20 %) ve svém odhadu maximálních ročních tržeb léku, které nadále odhaduje přibližně na jednu miliardu dolarů.
Roztroušená skleróza je chronické autoimunitní onemocnění postihující mozek a míchu. Nemoc může vést k široké škále fyzických, psychických i kognitivních obtíží a její průběh bývá velmi individuální. Podle odhadů americké organizace National Multiple Sclerosis Association s ní po celém světě žije 2,9 milionu lidí.
Novartis nyní plánuje zahájit registrační procesy na hlavních světových trzích. Podrobnější výsledky klinických studií mají být zveřejněny na odborném lékařském kongresu v Torontu ještě během letošního roku. Remibrutinib už je v současnosti schválen ve Spojených státech i Evropě pro léčbu chronické spontánní kopřivky.
Úmrtí pacientů v jiném programu
Vedle pozitivních zpráv však firma současně informovala o komplikacích v jiném vývojovém programu. Novartis dočasně zastavil nábor a léčbu pacientů ve studiích experimentální buněčné terapie rapcabtagene autoleucel (rap-cel neboli YTB323) určené pro autoimunitní onemocnění. Důvodem jsou tři úmrtí pacientů, která firma nyní vyhodnocuje z hlediska bezpečnosti.
U postižených pacientů se objevily závažné reakce spojené se syndromem IEC-HS, známou komplikací některých CAR-T buněčných terapií. Tento stav může vést k život ohrožujícím zánětlivým reakcím organismu.
Micron a SanDisk v předobchodní fázi oslabily, protože nové známky pokroku čínských výrobců pamětí znovu vyvolaly obavy z konkurence. Micron byl dolů asi 1,9 % a SanDisk zhruba 3 %.
Micron Technology and SanDisk stocks slipped in premarket trading on Tuesday as fresh evidence of China’s progress in memory chips revived concerns about competition.
Micron was down about 1.9% before the bell, while SanDisk fell roughly 3%. Both stocks entered September after 2026 gains driven by AI spending, tight supply and memory prices.
The immediate concern is ChangXin Memory Technologies, or CXMT, which has begun producing small quantities of HBM3E.
CXMT’s progress matters because high-bandwidth memory has become critical to AI computing.
The Chinese company is producing HBM3E in small quantities and plans to expand output in 2027.
Alibaba’s T-Head and Cambricon are testing the memory alongside their processors, with potential adoption next year if testing succeeds.
Micron, Samsung Electronics and SK Hynix are already moving into HBM4, leaving CXMT behind the leaders. Production scale and yields also remain hurdles, as Micron has been shipping HBM4 in volume since the first quarter.
That is why Bank of America analyst Vivek Arya remains bullish on Micron. TipRanks reported that Arya sees “limited competition” from CXMT in advanced AI memory because the Chinese supplier remains more exposed to consumer and commodity DRAM.
BofA retained a Buy rating and a $1,550 price target on Micron.
The risk is not that CXMT suddenly displaces Micron, but China is moving from lower-value memory into products generating the industry’s strongest margins.
For SanDisk, the more direct competitive issue is NAND flash.
Yangtze Memory Technologies, or YMTC, captured about 14% of global NAND bit shipments in the second quarter, according to Counterpoint Research, placing it third by shipment volume.
YMTC is targeting the top spot globally by the end of 2027 and is seeking 33 billion yuan, or about $5 billion, in an IPO to fund production upgrades and research.
That matters because additional NAND supply can influence global pricing even if Chinese producers remain restricted in the US.
Citi analyst Atif Malik has called Chinese capacity additions the biggest long-term risk to the memory thesis.
The analyst expects “both DRAM and NAND prices decelerating Q/Q in the next four quarters,” with prices potentially peaking around the second quarter of 2027.
This is a key issue for SanDisk investors. YMTC does not need to dominate enterprise storage to affect the broader NAND market.
Current fundamentals remain more supportive than the China angle suggests.
Mizuho said in an August research note that memory remains the “key bottleneck” in the semiconductor supply chain as aggregate DRAM demand rises.
The firm maintained Outperform ratings on Micron and SanDisk, with targets of $1,300 and $1,875.
There is also a reminder from last month’s selloff. When Micron and SanDisk dropped on reports that Apple could eventually source Chinese memory, Lynx Equity Research analyst KC Rajkumar called the reaction “an overreaction,” according to Investing.com.
Rajkumar pointed to supply constraints and customer qualification hurdles limiting the immediate threat from Chinese suppliers.
That distinction remains important. CXMT’s HBM3E output is still small, while Micron and its global peers are advancing into HBM4. YMTC has gained meaningful NAND volume, but remains more exposed to lower-value products than established rivals.
Britský regulátor pozastavil společnosti Amgen prodej Tavneosu novým pacientům kvůli nespolehlivým datům z klíčové studie. Schválení v Británii chce zrušit 1. března 2027.
Britain's medicines regulator on Tuesday suspended the use and sale of Amgen's (AMGN.O) rare-disease drug, Tavneos, to new patients, saying the main study supporting its approval was unreliable.
The drug, sold as Avacopan Vifor in Britain by CSL Vifor, is used with other medicines to treat severe autoimmune diseases that cause inflammation in small blood vessels and can damage the kidneys and lungs.
The regulator said unreliable data from the main trial meant the study could no longer prove the drug worked or that its benefits outweighed the risks. It plans to revoke the UK approval on March 1, 2027.
Patients already receiving the drug can continue for six months, while doctors consider alternatives, the regulator said, adding that it has advised patients not to stop treatment without consulting a specialist.
Tavneos was developed by ChemoCentryx, which Amgen acquired for $3.7 billion in 2022. Amgen holds the U.S. rights, while CSL Vifor holds commercial rights in selected markets outside the U.S., including Britain.
The European Commission revoked Tavneos' approval in August after regulators found the key trial data unreliable. The U.S. FDA has also proposed withdrawing the drug, citing unproven effectiveness and false statements in the original application.
Amgen is challenging the proposed U.S. withdrawal and has submitted more than 70 studies involving over 2,200 patients.
An independent review found Tavneos matched steroid-based treatment at 26 and 52 weeks, but did not confirm that it was better at 52 weeks. The U.S. FDA has also linked Tavneos to 76 cases of serious liver injury, including eight deaths.
Medtronic oznámil strategickou investici do Pi-Cardia až za 80 milionů USD a získá opci na převzetí firmy za odhadovaných až 210 milionů USD. Zároveň má být od roku 2027 výhradním globálním distributorem zařízení ShortCut pro komplexní TAVR.
, /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, and Pi-Cardia Ltd., a pioneer in leaflet modification technologies for structural heart disease, today announced a strategic investment by Medtronic in Pi-Cardia Ltd. With a focus on addressing the evolving needs of increasingly complex transcatheter aortic valve replacement (TAVR) patients and procedures, Medtronic secures an option for strengthening its structural heart portfolio through this strategic investment, supporting the next generation of innovation.
Pi-Cardia ShortCut™ Device Pi-Cardia's ShortCut™ device is the first FDA-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction. The device provides physicians with a safe, easy-to-learn, reproducible approach to leaflet modification that can help preserve coronary access and enable future transcatheter valve procedures. In FDA-reviewed clinical studies, ShortCut™ demonstrated successful leaflet splitting in all pivotal trial patients and a favorable safety profile.
"As structural heart care evolves, we're investing in technologies that help physicians address today's challenges while preparing for tomorrow's opportunities," said Jorie Soskin, vice president and general manager of the Structural Heart business within Medtronic's Cardiovascular portfolio. "Our investment in Pi-Cardia reflects our commitment to building a portfolio of technologies that will shape the future of TAVR, particularly for patients with complex anatomy. We believe leaflet modification technologies like ShortCut have the potential to become an important component of structural heart care and the future of TAVR as transcatheter therapies continue to advance."
Under the agreement, Medtronic will make strategic investments of up to $80 million into Pi-Cardia and is expected to become the exclusive global commercial distributor of the ShortCut device in 2027. Medtronic will leverage its worldwide Structural Heart organization to expand physician access across the United States, Europe, Japan and other international markets. The agreement also includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, subject to customary adjustments, plus additional potential earn-out payments post-acquisition that could meaningfully increase the total consideration. The transactions are subject to regulatory approval and customary closing conditions.
"Our mission has been to make leaflet modification a standard part of complex TAVR," said Erez Golan, Chief Executive Officer of Pi-Cardia. "Medtronic is the right partner to help us achieve this vision given their global reach and commitment to bringing innovative tools to physicians and patients worldwide. We are confident this collaboration will accelerate adoption of ShortCut while continuing to advance the future of leaflet modification."
The strategic investment secures an option for Medtronic to strengthen its structural heart portfolio by adding a first-of-its-kind technology that addresses a significant challenge in valve-in-valve TAVR while complementing the company's leadership in transcatheter valve therapies. It also reflects Medtronic's commitment to partnering and investing early in innovations that can improve patient outcomes, expand future treatment options, and support long-term growth.
Pi-Cardia was founded by Erez Golan and Eyal Kolka, and is backed by experienced medtech investors including Sofinnova Partners, Sprig Equity, and Jacques Séguin, whose commitment has helped advance the company's vision of developing transformative leaflet modification technologies.
About Pi-Cardia
Pi-Cardia Ltd. is a privately held medical device company dedicated to developing innovative structural heart technologies that address unmet clinical needs. Its proprietary leaflet modification platform is designed to improve procedural outcomes and expand treatment options for patients undergoing transcatheter valve interventions.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission, to alleviate pain, restore health, and extend life, unites a global team of employees dedicated to transforming healthcare and improving lives around the world.
Contacts:
Kimberly Powell
Public Relations
+1-202-498-2601
Ingrid Goldberg
Investor Relations
+1-763-505-2696
Broadcom stock has dropped to a crucial support level, and the upcoming earnings report will help to determine whether the recent retreat will continue or whether the shares will rebound. AVGO trades at $370, down by 25% from its highest point this year.
Broadcom has become one of the biggest technology companies globally, with its market capitalization soaring to over $1.7 trillion. It owns top companies like VMware, CA Technologies, Symantec, and Broadcom Communications.
The company has emerged as a major player in the artificial intelligence industry, driven by a growing network of strategic partnerships. Most recently, it unveiled Jalapeño, a custom chip developed for OpenAI, which reportedly outperformed Nvidia’s chips in certain performance benchmarks.
Broadcom counts the biggest companies in the world, including large names like Apple, Alphabet, Anthropic, and Microsoft. These partnerships, together with its acquisitions, have helped its revenue continue rising. Its annual revenue has jumped from $27.5 billion in 2021 to $75.4 billion in the trailing twelve months.
The most recent results showed that Broadcom’s revenue jumped by 48% in the second quarter of the year to over $22.18 billion. This growth was driven by a 143% YoY gain from its AI semiconductor business.
All signs are that the company’s business continued growing in the third quarter as the artificial intelligence spending accelerated. All of its top customers published strong numbers and guidance.
For example, Apple announced strong financial results, and this growth may continue as it launches a new foldable phone. Also, companies like Google and Amazon all committed to keep spending.
Yahoo Finance data shows that analysts expect the upcoming results to show that its revenue soared by 84% last quarter to $29 billion. Its earnings-per-share (EPS) is also expected to move from $1.69 in Q3’25 to $3.24. Broadcom has a long record of doing better than expected.
Analysts are highly optimistic about Broadcom, with most who track it having a bullish outlook. Royal Bank of Canada has a target of $400, while BMO has a target of $455. The most optimistic analyst is from Evercore who sees the shares jumping to $582, up sharply from where it is today. In a statement this week, BakerAvenue’s King Lip called Broadcom a top pick ahead of its earnings.
The main issue, however, is that Broadcom’s valuation has become quite expensive, meaning that it will need to announce a big beat and raise, and possibly, a bigger buyback.
The company trades with a forward price-to-earnings ratio of 31.7, higher than the sector median of 22.6. Its multiple is also higher than the five-year average. It is also higher than that of other technology companies like Nvidia and Micron.
Broadcom stock | Source: TradingView
The daily chart shows that the AVGO stock peaked at $494 in June and formed an abandoned baby pattern. This pattern is usually one of the most common bearish reversal signs in technical analysis.
The stock has now plunged and found a strong support level of $356, its lowest level on July 2nd and August 26. This could be a sign that it has formed a double-bottom pattern, a common bullish reversal sign. This support is also along the 61.8% Fibonacci Retracement level and the 200-day moving average.
Therefore, the stock will likely bounce back in the coming days, potentially to the psychological level of $400.
SpaceX a AST SpaceMobile tlačí satelitní mobilní sítě, ale článek tvrdí, že neohrozí husté městské pokrytí ani cash flow věžových REITů. Crown Castle a American Tower mají zůstat oporou díky fyzickým limitům orbitálních sítí.
The direct-to-device space economy entered a new competitive phase in August 2026.
SpaceX Today
$143.73 +2.23 (+1.58%)
As of 08/31/2026 04:00 PM Eastern
$104.83▼
$225.64$220.20
SpaceX NASDAQ: SPCX formally outlined ambitions to challenge telecom giants with Starlink Mobile, while competitors race to get their own satellite arrays ready for consumer availability.
This escalation naturally raises questions about the future of traditional ground infrastructure. If cellular coverage blankets the globe from low-Earth orbit, investors rightly wonder whether the steel towers anchoring modern telecommunications will face sudden obsolescence.
Get Crown Castle alerts:
The market has occasionally punished earthbound telecom stocks on the premise of satellite disruption. Beneath the headlines, however, lies a harsh physical and financial reality. The physics of bandwidth and the capital required to replicate urban network density suggest a very different outcome.
Ground-level macro towers are not being replaced; they are being complemented. By examining the limitations of space-based networks, a clear picture emerges of why terrestrial incumbents maintain a moat over satellite challengers.
Orbital Telecom Vs. Terrestrial YieldsThe telecommunications sector is experiencing a structural shift as orbital assets come online. Translating that shift into portfolio strategy requires looking past the launch hype and focusing heavily on capital allocation and network physics.
Firing the First Shot in the Satellite Telecom WarThe timeline for space-based cellular is accelerating as we approach the end of summer. During a highly anticipated August 2026 earnings call, SpaceX management detailed plans for a competitive terrestrial network.
The primary goal is to leverage Starlink's expanding orbital footprint to beam connectivity directly to unmodified consumer smartphones worldwide. This builds on the approximately $19.6 billion mid-band spectrum acquisition SpaceX made from EchoStar, transitioning the aerospace firm from shared spectrum agreements to owning exclusive bandwidth.
SpaceX is not alone in this orbital land grab. AST SpaceMobile NASDAQ: ASTS recently deployed its latest BlueBird satellites, securing a targeted fourth-quarter commercial launch alongside US Mobile. These technological milestones successfully address the rural coverage divide, a persistent headache for legacy carriers.
Beaming a signal from space easily connects a hiker in Wyoming or a rural farming operation. The disruption narrative currently weighing on the market suggests these deployments will eventually bleed into high-density suburban and urban markets, eating into the core market share of ground-based operators.
The $130 Billion Reality CheckProviding text messages to remote areas is a solved problem. Streaming high-definition video in a packed metropolitan stadium via satellite is an entirely different physics equation. Low-Earth orbit satellites face severe spectrum constraints and signal degradation when attempting to penetrate urban foliage, thick concrete buildings, and severe weather systems.
Bank of America NYSE: BAC recently issued a decisive defense of legacy infrastructure, noting that SpaceX's proposed network topology would be difficult to scale for high-density capacity. The company has proposed consumer-mounted femtocells to bypass standard towers. The financial barrier to scaling this technology, however, would be steep. Bernstein analysts estimate that building a standalone mobile network to rival existing carriers would require roughly $50 billion to $130 billion in capital expenditures.
To replicate the dense capacity of existing outdoor networks without traditional cell towers, operators would theoretically need hundreds of millions of micro-receivers scattered across the country. Satellite telecom is poised to act as a crucial, highly profitable complementary layer designed to close global dead zones. However, it currently lacks the physical capacity to carry the terabytes of data generated by urban centers without macro-tower power, heavy fiber backhaul, and established municipal permitting.
Crown Castle's 5.6% Yield Is Hiding in Plain SightThis physical limitation creates a highly favorable environment for restructured terrestrial operators. Crown Castle NYSE: CCI recently executed a fundamental pivot, selling its fiber and small-cell segments to EQT Holdings and Zayo for approximately $8.5 billion. By shedding these capital-intensive divisions, Crown Castle transformed back into a pure-play United States macro tower real estate investment trust (REIT).
Crown Castle Today
CCI
Crown Castle
$76.25 +0.11 (+0.14%)
As of 08/31/2026 03:58 PM Eastern
$69.72▼
$100.505.57%
38.71
$95.13
Management used this strategic divestiture to reset Crown Castle's capital allocation framework. The annualized dividend was adjusted to roughly $4.25 per share, establishing a highly sustainable adjusted funds from operations payout ratio of around 75% to 80%. Currently trading near $76, the stock offers an estimated 5.6% yield.
Recent intrinsic value models suggest Crown Castle trades at a severe discount, approaching 33% below discounted cash flow estimates. The market has temporarily mispriced the REIT due to the combination of its dividend reset and misplaced fears regarding satellite disruption. For value-oriented investors, Crown Castle represents a streamlined infrastructure asset operating securely within a well-established moat.
American Tower's Defensive EdgeWhile Crown Castle focuses entirely on the domestic market, American Tower NYSE: AMT leverages its global footprint and strategic balance sheet management to defend its position. Recognizing shifting macroeconomic headwinds in emerging markets in early 2024, American Tower management decided to temporarily pause its long-running streak of aggressive dividend growth.
American Tower Today
AMT
American Tower
$175.94 -0.29 (-0.16%)
As of 08/31/2026 03:58 PM Eastern
$160.06▼
$205.214.07%
24.20
$215.29
That period of financial conservatism proved strictly temporary. American Tower resumed its dividend growth trajectory in March 2025, bumping the quarterly payout to $1.70 per share. As of March 2026, the cash distribution was raised further to $1.79 per share. With shares currently trading around $176, this renewed dividend expansion signals management’s confidence in the underlying business model, shrugging off the perceived threat of orbital telecom disruption.
By deleveraging during that 2024 pause, American Tower created the financial flexibility required to absorb incoming capital expenditure demands.
The enterprise is actively investing in edge computing data centers situated at the base of its existing cell towers.
This edge strategy acts as a direct hedge against localized telecom disruption. As artificial intelligence applications demand lower latency and higher processing power at the local level, American Tower is transforming its real estate into decentralized computing hubs. This evolution helps ensure that American Tower remains indispensable to modern data transmission, regardless of whether a signal originates from a nearby cell phone or a low Earth orbit satellite.
Positioning Portfolios for the Telecom Infrastructure ShiftThe commercialization of space-based mobile networks is an undeniable technological triumph. Companies launching these satellites will likely generate substantial revenue by connecting the most remote regions of the world and partnering with existing telecom giants to fill coverage gaps.
However, the terrestrial cell tower remains the undisputed backbone of global, high-density telecommunications. The physical necessity of ground-level power, fiber connections, and raw localized bandwidth protects the cash flows of incumbent tower operators.
Investors may want to monitor pure-play tower REITs such as Crown Castle and diversified operators such as American Tower, as their current valuations appear disconnected from the enduring reality of their infrastructure moats. Evaluating these equities during periods of satellite-driven market noise could provide a strategic entry point before the market fully prices in the limitations of orbital bandwidth.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Crown Castle Right Now?Before you consider Crown Castle, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crown Castle wasn't on the list.
While Crown Castle currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Stoke Therapeutics a Biogen oznámily, že čtyřletá data podporují potenciál zorevunersenu u Dravetova syndromu: přetrvaly zlepšení kognice a chování spolu s trvalým snížením četnosti záchvatů.
–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–
–Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile–
–New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life–
BEDFORD, Mass. and CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5–9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. The global, pivotal Phase 3 EMPEROR study is underway to evaluate the safety and efficacy of zorevunersen, and results are anticipated in the third quarter of 2027.
Data to be shared at EEC include the first medical meeting presentation of 4-year results from the ongoing Phase 1/2a open-label extension (OLE) studies of zorevunersen in patients with Dravet syndrome. Improvements in cognition and behavior were sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile. New exploratory sub-analyses show effects on the most severe seizure types, which are the leading risk factor for sudden unexpected death in epilepsy (SUDEP)1, as well as improvements in quality of life for patients treated with zorevunersen.
"Together with the Phase 1/2a results, the ongoing OLE studies provide more than 5 years of clinical data that continue to deepen our understanding of zorevunersen’s long-term safety and benefits,” said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics. “These data have consistently shown substantial and durable seizure reductions with continued treatment. For the first time at EEC, we will share an additional analysis showing zorevunersen’s effects on the most severe seizure types. Alongside continuing improvements in cognition and behavior over time, these new findings support the potential of zorevunersen to change the course of Dravet syndrome by targeting the underlying genetic cause of the disease.”
“Dravet syndrome is a devastating neurodevelopmental disease that impacts nearly every aspect of daily life for patients and those who care for them,” said Stephanie Fradette, Pharm.D., Head of the Rare Neurology Development Unit at Biogen. “The data shared at EEC provide continued support for the potential of zorevunersen to give people living with Dravet syndrome the possibility of more neurotypical development. We look forward to discussing these data with the epilepsy community at EEC.”
Details of the EEC presentations are as follows:
Title: Zorevunersen Demonstrates Disease-Modifying Potential in Patients with Dravet Syndrome with Improvements in Seizure Burden, Quality of Life, and Overall Clinical Status
Oral Presentation Date & Time: Sunday, September 6, 12:53-1:02 PM EEST/ UTC+3 (5:53-6:02 AM ET)Oral Presenter: J. Helen Cross, MB ChB, Ph.D., Professor, The Prince of Wales’s Chair of Childhood Epilepsy and Head of the Developmental Neuroscience Programme at University College London Great Ormond Street Institute of Child Health, Honorary Consultant in Paediatric Neurology and Past President of the International League Against Epilepsy Title: Zorevunersen Demonstrates Potential as a Disease-Modifying Therapy in Patients with Dravet Syndrome: A Matching-Adjusted Indirect Comparison Between Natural History and Patients Receiving Zorevunersen
Poster Presentation Date & Time: Monday, September 7, 2:00-3:00 PM EEST/ UTC+3 (7:00-8:00 AM ET)Poster Presenter: Andreas Brunklaus, MD, Consultant Paediatric Neurologist at the Royal Hospital for Children in Glasgow, Honorary Professor at the University of Glasgow
Poster Number: P0803 Title: Zorevunersen Demonstrates Potential as a Disease-Modifying Therapy in Patients with Dravet Syndrome Through Durable Seizure Reduction and Improvements in Cognition, Behavior, and Quality of Life Through 48 Months of Treatment in Open-Label Extension Studies
Poster Presentation Date & Time: Tuesday, September 8, 2:00-3:00 PM EEST/ UTC+3 (7:00-8:00 AM ET)Poster Presenter: Elaine Wirrell, MD, Director of Pediatric Epilepsy at Mayo Clinic, Director of the Child and Adolescent Neurology Residency Training Program at Mayo Clinic
Poster Number: P0797 Summary of Zorevunersen Safety Data
Following treatment in the Phase 1/2a studies, 93% (75/81) patients continued treatment in one of two OLE studies. As of the 4-year data cutoff, 77% (58/75) patients remained in these studies.Zorevunersen continues to be generally well tolerated, with some patients treated for more than 5 years in the Phase 1/2a and ongoing OLE studies. As of July 31, 2026, more than 930 doses have been administered.Elevated CSF protein lab values occurred in approximately 94% of patients of which 59% have been classified as a treatment-emergent adverse event. Importantly, no serious or severe clinical manifestations have been associated with CSF protein elevations. There have been no reports of hydrocephalus. About Dravet Syndrome
Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent seizures as well as significant cognitive and behavioral impairments. Most cases of Dravet are caused by mutations in one copy of the SCN1A gene, leading to insufficient levels of NaV1.1 protein in neuronal cells in the brain. Even when treated with the best available anti-seizure medicines (ASMs), up to 57 percent of patients with Dravet syndrome do not achieve ≥50 percent reduction in seizure frequency. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. Developmental and cognitive impairments often include intellectual disability, developmental delays, movement and balance issues, language and speech disturbances, growth defects, sleep abnormalities, disruptions of the autonomic nervous system and mood disorders. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP; up to 20 percent of children and adolescents with Dravet syndrome die before adulthood due to SUDEP, prolonged seizures, seizure-related accidents or infections 2. Dravet syndrome occurs globally and is not concentrated in a particular geographic area or ethnic group. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S. (~16,000), UK, EU-4 and Japan 3. There are no approved disease-modifying therapies for people living with Dravet syndrome.
About Zorevunersen
Zorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing functional NaV1.1 protein production in brain cells from the unaffected (wild-type) copy of the SCN1A gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function in the SCN1A gene, and China’s Center for Drug Evaluation has granted zorevunersen Breakthrough Therapy Designation. Stoke has a strategic collaboration with Biogen (Nasdaq: BIIB) to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights. Zorevunersen is currently in clinical development, and its safety and efficacy have not been evaluated by any regulatory authority.
About the Phase 1/2a and Open-Label Extension Studies
Two Phase 1/2a open-label, multicenter studies evaluated the effects of zorevunersen in patients with highly refractory Dravet syndrome ages 2 to 18 years (N=81). Primary endpoints were the safety profile, plasma pharmacokinetics (PK) and exposure in cerebrospinal fluid (CSF) of single and multiple doses of zorevunersen. Secondary endpoints included percentage change from baseline in major motor seizure frequency, overall clinical status (a measure of patients’ overall functioning) and quality of life. The ADMIRAL Phase 1/2a study included an exploratory endpoint to evaluate changes in neurodevelopmental status (cognition & behavior) as measured by Vineland Adaptive Behavior Scales, Third Edition (Vineland-3). The Phase 1/2a studies were completed in November 2023. Following treatment in the Phase 1/2a studies, eligible patients continued treatment with zorevunersen every four months in one of two OLEs. There was at least a 6-month gap between the last dose administered in the Phase 1/2a studies and the first dose administered in the OLEs. The primary endpoints are the safety profile of multiple doses of zorevunersen. Secondary endpoints include PK parameters, percentage change from baseline in major motor seizure frequency, change in overall clinical status, and change from baseline in quality of life. Exploratory endpoints include changes in neurodevelopment status as measured by Vineland-3. Results from the Phase 1/2a and OLE studies were published in The New England Journal of Medicine (NEJM) in March 2026. The OLE studies are ongoing.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow us on LinkedIn.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, Instagram, LinkedIn, X, YouTube.
Stoke Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the ability of zorevunersen to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior and cognition at the indicated dosing levels or at all; the potential benefits, safety and efficacy of zorevunersen; the design, timing and expected progress of clinical trials, data readouts, regulatory meetings, regulatory decisions and other presentations; and the participation of scientists associated with Stoke making presentations at EEC and the presentation of data at EEC. Statements including words such as “plan,” “potential,” “will,” “continue,” “expect,” or similar words and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause Stoke’s results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: Stoke’s ability to advance, obtain regulatory approval and ultimately commercialize its product candidates; that if Biogen were to breach or terminate the collaboration, Stoke would not obtain the anticipated financial or other benefits; the possibility that Stoke and Biogen may not be successful in their development of zorevunersen and that, even if successful, they may be unable to successfully commercialize zorevunersen; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; Stoke’s ability to protect its intellectual property; Stoke’s ability to fund development activities and achieve development goals into 2028; and the other risks and uncertainties described under the heading “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2025, its quarterly reports on Form 10-Q, and the other documents it files with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Stoke undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Biogen Safe Harbor
This news release contains forward-looking statements, including, among others, relating to: the potential clinical effects of zorevunersen; the potential for zorevunersen to change the course of Dravet syndrome and improve outcomes for patients; the expected timing of Phase 3 study results; the potential benefits, safety and efficacy of zorevunersen; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of the underlying causes of Dravet syndrome; the anticipated benefits, risks and potential of Biogen's collaboration arrangements with Stoke Therapeutics; the potential of Biogen's commercial business and pipeline programs, including zorevunersen; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.
These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.
These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
Biogen Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.
References:
Beniczky, S. et al. Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy. Epilepsia. 2025; 1804–1823.Symonds, J. et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants. Brain. 2021;144(9):2879-2891.Based on Stoke Therapeutics’ preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific mortality. The estimate is based on incidence rates published by Wu et al., Pediatrics, 2015.
The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) designation, providing enhanced agency engagement throughout development and eligibility for accelerated approval and priority reviewPhase 3 design fully aligned with FDA; Biologics License Application (BLA) filing anticipated in 2028OCU410 is designed as a one-time subretinal gene therapy that addresses multiple disease pathways, offering a differentiated approach from approved complement inhibitors in the U.S. which address individual disease pathways and require ongoing intravitreal injections MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for GA secondary to dry age-related macular degeneration (dAMD). The Company also highlighted the recent FDA RMAT designation for OCU410, which supports a potential accelerated development and review pathway for the program.
“Dosing the first patient in our global Phase 3 trial, just weeks after receiving RMAT designation, marks a defining moment for the OCU410 program – and for the millions of people living with geographic atrophy. Outside the U.S., there are currently no approved treatments for GA, while in the U.S., available treatment options address only one of the four disease pathways and require ongoing, repeated eye injections,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. “This is our third modifier gene therapy program to advance into late-stage development, demonstrating the strength of our platform and our vision for potentially delivering a one-time treatment for life.”
The initiation of dosing follows the successful completion of a Type B End-of-Phase 2 (EOP2) meeting with FDA’s Center for Biologics Evaluation and Research (CBER) in July 2026, resulting in alignment on all critical Phase 3 design elements, including primary and secondary endpoints, dose, adaptive design, and a single pivotal trial pathway to support a BLA.
“We are entering a global single Phase 3 with a well-defined program: a dose validated in a randomized, controlled Phase 2 study; an FDA-endorsed primary endpoint measuring the rate of lesion growth; and a secondary endpoint assessing functional vision,” said Mohamed Genead, MD, Chief Medical Officer of Ocugen. “The Phase 3 program builds on compelling 12-month Phase 2 data, which demonstrated a statistically significant 31% reduction in lesion growth with the optimal dose compared with control following a single subretinal injection, along with concordant preservation of the ellipsoid zone and no drug-related serious adverse events (SAEs) or adverse events of special interest (AESIs).”
OCU410 delivers the human retinoid-related orphan receptor alpha (RORA) modifier gene via a single subretinal injection of an AAV5 vector. Unlike therapies targeting a single pathway, OCU410 is designed to simultaneously address multiple pathophysiological drivers of GA-complement overactivation, chronic inflammation, oxidative stress, and lipid dysregulation. GA affects approximately 2–3 million people in the U.S. and Europe and is a leading cause of irreversible central vision loss in older adults, with prevalence expected to rise as the population ages.
According to study investigator Victor Gonzalez, MD, “Patients with geographic atrophy continue to face irreversible structural and functional loss of the retina, along with limited treatment options. The OCU410 Phase 3 study provides an important opportunity to evaluate a novel, potential one-time gene therapy approach that could lessen the burden of current treatments in the U.S., which require patients to undergo multiple injections every year.”
Global Phase 3 Registrational Trial Design
The Phase 3 trial is a global, multicenter, randomized, controlled study enrolling 237 subjects with GA secondary to dAMD, randomized 2:1 to a single 200 µL subretinal injection of OCU410 (5×1010 vg/mL) or an untreated control arm, with sites in the United States, Canada, Europe, and Latin America.
Primary endpoint: Rate of change of square root-transformed GA lesion area (√mm²/year) by fundus autofluorescence (FAF) at baseline, Month 4, Month 8, and Month 12, analyzed by MMRM.Secondary endpoints: Proportion of subjects with Low-Luminance Visual Acuity (LLVA) loss ≥15 ETDRS letters at two consecutive visits through Month 12, providing a functional vision anchor to the primary anatomic endpoint; and rate of change of ellipsoid zone (EZ) area loss by SD-OCT.Regulatory path: A single, adequate and well-controlled Phase 3 trial, aligned with FDA feedback, is intended to support a BLA filing anticipated in 2028. Discussions are ongoing with the European Medicines Agency (EMA) regarding alignment to potentially support a marketing authorization application (MAA) in Europe with this single Phase 3 trial.
RMAT Designation: Regulatory and Strategic Significance
On July 29, 2026, FDA granted RMAT designation to OCU410 based on Phase 2 clinical data demonstrating clinically meaningful efficacy and a favorable safety profile, with no serious adverse events related to OCU410 reported. RMAT designation is granted to regenerative medicine therapies intended to treat serious or life-threatening conditions where preliminary clinical evidence indicates the potential to address an unmet medical need.
For the OCU410 program, RMAT designation provides:
Eligibility for accelerated approval and priority review, which may compress the time from BLA submission to potential market entry.All benefits of Breakthrough Therapy designation, including intensive FDA guidance on efficient development and organizational commitment involving senior FDA leadership.Early and frequent FDA interactions on the use of surrogate and intermediate clinical endpoints reasonably likely to predict long-term clinical benefit-directly relevant to OCU410’s FAF-based anatomic primary endpoint.Potential flexibility in satisfying post-approval requirements, including through expanded patient registries or real-world evidence. Taken together with FDA alignment on the Phase 3 design and the initiation of dosing, RMAT designation further de-risks the regulatory pathway for OCU410 and reinforces the differentiation of a one-time, multi-pathway gene therapy in a GA market currently served only by chronically administered intravitreal complement inhibitors.
Supporting Phase 2 ArMaDa Data
The Phase 3 trial and the RMAT designation are supported by 12-month data from the Phase 2 ArMaDa trial (NCT06018558), a multicenter, randomized, controlled study of 51 subjects with GA secondary to dAMD.
Lesion growth (FAF): 31% reduction in GA lesion area growth rate in the medium dose group versus control at 12 months (p < 0.05) in the pivotal phase 3 population (lesion size of ≥2.5 mm2 and ≤17.5 mm2), a potential 2× treatment benefit relative to the 15% and 22% reductions reported for currently approved therapies in the U.S. at 12 and 24 months, respectively.EZ preservation (SD-OCT): 27% reduction in ellipsoid zone area loss in the medium dose group versus control, a structural correlate of visual function.Responder analysis: In the medium dose group, approximately 20% of treated subjects showed no disease progression; 75% demonstrated >30% reduction in lesion growth at 12 months.Safety: No OCU410-related serious adverse events (SAEs) or adverse events of special interest (AESIs) reported to date. About OCU410
OCU410 (AAV5-hRORA) is Ocugen’s investigational first-in-class modifier gene therapy, delivering the RORA gene via a single unilateral subretinal injection to regulate complement activation, neuroinflammation, oxidative stress, and lipid metabolism – multiple pathways implicated in the pathogenesis of GA. OCU410 has received RMAT designation from the FDA and Advanced Therapy Medicinal Product classification from the European Medicines Agency's Committee for Advanced Therapies.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on LinkedIn and X.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of enrollment and data readouts, the ability to initiate new clinical programs, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen’s product candidates, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that receipt of RMAT designation may not lead to faster development or accelerated regulatory review or approval; that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our annual and quarterly filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
FuelCell Energy zveřejní výsledky za 3. čtvrtletí před otevřením trhu; analytici čekají ztrátu 39 centů na akcii a tržby 38,82 milionu USD. Akcie v pondělí klesly o 3 % na 17,23 USD.
FuelCell Energy, Inc. (NASDAQ:FCEL) will release its third quarter earnings report before the opening bell on Wednesday, Sept. 2.
Analysts expect the Danbury, Connecticut-based company to report a quarterly loss of 39 cents per share, versus a loss of $1.02 per share in the year-ago period. The consensus estimate for FuelCell Energy’s quarterly revenue is $38.82 million. It reported $46.74 million last year, according to Benzinga Pro.
On July 9, FuelCell Energy announced a collaboration with Siemens to accelerate the growth of fuel cell-based power generation.
Shares of FuelCell Energy fell 3% to close at $17.23 on Monday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
UBS analyst Manav Gupta upgraded the stock from Neutral to Buy and raised the price target from $22 to $27 on July 14, 2026. This analyst has an accuracy rate of 74%. B. Riley Securities analyst Ryan Pfingst upgraded the stock from Neutral to Buy and increased the price target from $13 to $32 on June 29, 2026. This analyst has an accuracy rate of 62%. Wells Fargo analyst Praneeth Satish maintained an Underweight rating and raised the price target from $6 to $8 on June 16, 2026. This analyst has an accuracy rate of 57%. Jefferies analyst Laurance Alexander maintained a Hold rating and boosted the price target from $7.2 to $16 on June 10, 2026. This analyst has an accuracy rate of 74%. Canaccord Genuity analyst George Gianarikas upgraded the stock from Hold to Buy and increased the price target from $12 to $30 on June 9, 2026. This analyst has an accuracy rate of 59%. Trending
Considering buying FCEL stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Helix a Hornbeck dokončily fúzi výměnou akcií a vytvořily integrovanou offshore servisní společnost. Nový Hornbeck Offshore Services začne na NYSE obchodovat 2. září 2026 pod tickerem HOS.
Hornbeck Offshore Services, Inc. To Begin trading on NYSE Under "HOS" on September 2, 2026
, /PRNewswire/ -- Helix Energy Solutions Group, Inc. ("Helix") (NYSE: HLX) and Hornbeck Offshore Services, Inc. ("Hornbeck") today announced they have completed the previously announced combination in an all-stock transaction, establishing a premier integrated offshore services company.
The combined company has assumed the Hornbeck Offshore Services, Inc. name and will begin trading on the New York Stock Exchange on September 2, 2026, under the ticker symbol "HOS." Helix's common stock will cease trading on the New York Stock Exchange under the ticker symbol "HLX" at the close of trading on September 1, 2026.
As previously announced, Todd M. Hornbeck has assumed the role of President, Chief Executive Officer and Director of the combined company, and William L. Transier has assumed the role of Chairman of the combined company's Board of Directors. In addition, the combined company has appointed the following individuals to the executive leadership team:
R. Potter Adams, Executive Vice President and Chief Financial Officer; Scott "Scotty" A. Sparks, Executive Vice President and Chief Operating Officer – Subsea Services and Well Intervention Ben D. Todd, Executive Vice President and Chief Operating Officer – Marine Transportation and Specialty Samuel A. Giberga, Executive Vice President, General Counsel and Secretary; Brian M. Cook, Executive Vice President and Chief Accounting Officer; Priscilla B. Heistad, Executive Vice President and Chief Human Resources Officer; Daniel M. Stuart, Executive Vice President and Chief Commercial Officer; Carl G. Annessa, Executive Vice President – Defense / Emerging Technologies; and Michael J. Nicaud, Senior Vice President, Associate General Counsel and Chief Compliance Officer "Today marks the beginning of an exciting new chapter for our company, our employees, our customers and our shareholders," said Todd M. Hornbeck, President and CEO of Hornbeck Offshore Services, Inc. "By bringing together Hornbeck's industry-leading marine expertise with Helix's differentiated robotics, well intervention and subsea capabilities, we have created a global offshore services leader, providing innovative and integrated solutions to our customers across the deepwater oilfield, defense and renewables industries. I want to thank the employees of both organizations for their professionalism and commitment throughout this process. Together, we are building a stronger, more diversified company with the scale, capabilities and financial strength to capitalize on opportunities across our offshore markets while delivering long-term value for our shareholders."
"The closing of this transaction represents the successful culmination of a shared vision to create a market-leading offshore services company with unique capabilities and strategic flexibility," said William L. Transier, Chairman of the Board of Hornbeck Offshore Services, Inc. "The merger brings together two highly complementary organizations with strong cultures, exceptional people and deep customer relationships. On behalf of the Board, I am grateful to our shareholders for their support and confidence. We believe this merger positions the company to generate sustainable growth and to create significant value for all stakeholders."
Advisors
Goldman Sachs & Co. LLC served as financial advisor to Helix, and Veriten LLC served as an independent strategic advisor. Baker Botts L.L.P. served as legal counsel to Helix, and Joele Frank, Wilkinson Brimmer Katcher served as its strategic communications advisor.
Barclays, Piper Sandler & Co. and J.P. Morgan acted as financial advisors to Hornbeck. Kirkland & Ellis LLP and Jones Walker LLP served as its legal counsel.
About Hornbeck Offshore Services
Hornbeck Offshore Services, Inc. is a global offshore services leader, providing innovative and integrated marine and subsea solutions to customers across the deepwater oilfield, defense and renewables industries.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present or historical fact included in this press release are forward-looking statements. Words such as "anticipate," "believe," "expect," "intend," "may," "plan," "project," "should," "will" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words, and the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements include, but are not limited to, statements regarding: the combined company's expectations, hopes, beliefs, intentions or strategies regarding the combined company's growth and stakeholder value; the timeline and ability to realize anticipated benefits and expected synergies of the merger; and equity award grants.
Forward-looking statements are based on current expectations and assumptions and involve known and unknown risks, uncertainties and other important factors, many of which are beyond the combined company's control, including, but not limited to, risks related to potential litigation relating to the merger, including the effects of any outcomes related thereto; the ability of the combined company to retain and hire key personnel, to retain customers or maintain relationships with Helix's or Hornbeck's respective suppliers and customers; the diversion of management's time and attention from ordinary course of business operations to the integration of Helix's and Hornbeck's businesses and the ability to achieve the anticipated synergies and value-creation contemplated by the merger; potential adverse reactions or changes to business relationships resulting from the completion of the merger; legislative, regulatory and economic developments; potential business uncertainty, including changes to existing business relationships, following the completion of the merger that could affect the combined company's financial performance as well as unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, losses, synergies, economic performance, indebtedness, financial condition, future prospects, business and management strategies, expansion and growth of the combined company's businesses; actions by governments, regulatory authorities, customers, suppliers and partners; market conditions; demand for services; the performance of contracts by suppliers, customers and partners; operating hazards and delays, which includes delays in delivery, chartering or customer acceptance of assets or terms of their acceptance; complexities of global political and economic developments; the impact of general economic conditions, including inflation, on economic activity and on the combined company's operations; the general volatility of oil and natural gas prices and cyclicality of the oil and gas industry' and other risks described from time to time in Helix's and the combined company's filings with the SEC.
Forward-looking statements speak only as of the date they are made. The forward-looking statements in this press release are based upon information available to the combined company as of the date of this press release and, while the combined company believes such information forms a reasonable basis for such statements, these statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. Actual outcomes may vary materially from those described in these statements. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the combined company's periodic filings with the SEC, including Helix's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and in Helix's Definitive Proxy Statement/Prospectus filed with the SEC on July 31, 2026. The combined company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements, other than as may be required by applicable law or regulation.
Contacts:
[email protected]
Potter Adams
Executive Vice President and CFO
985-727-6815
Brent Arriaga
Vice President of Finance and Investor Relations
281-618-0460
LNG Energy Group prodloužila závaznou exkluzivitu a LOI s Fifth Ocean do 30. listopadu 2026, zatímco dokončují due diligence na společný JV v USA pro investice do ropy a plynu ve Venezuele. Fifth Ocean má financovat až 200 milionů USD.
Not for distribution to United States newswire services or for dissemination in the United States
TORONTO, ON / ACCESS Newswire / September 1, 2026 / LNG Energy Group Corp. (TSXV:LNGE)(TSXV:LNGE.WT)(OTC PINK:LNGNF)(FWB:E26) (the "Company" or "LNG Energy Group") announces that, further to its news release dated May 26, 2026, it has reached an agreement with Fifth Ocean Management LP, in partnership with Westlawn Group (together, "Fifth Ocean"), to extend the term of the binding exclusivity agreement and Letter of Intent ("LOI") to November 30, 2026 while the parties finalize due diligence, seek to satisfy all conditions precedent and negotiate in good faith definitive transaction documentation.
Under the terms of the previously announced proposed joint venture, the parties will establish a new joint venture company (the "JV Company") organized in the United States to invest in oil and gas exploration and development projects in Venezuela. The JV Company will be owned 50/50 between the Company and Fifth Ocean, the Company will contribute existing oil and gas assets in Venezuela, and Fifth Ocean will fund an investment program of up to US$200 million to increase production and potential acquisition of additional assets in Venezuela (the "Transaction").
The Transaction is subject to the completion of due diligence and certain conditions precedent including the negotiation and entry into the mutually acceptable definitive documentation within the binding exclusivity period. Closing of the Transaction is subject to customary conditions precedent, required regulatory approvals (including applicable Office of Foreign Assets Control ("OFAC"), Ontario Securities Commission and TSX Venture Exchange) and customary contractual approvals.
The JV Company will also partner with Salamander Solutions Inc. ("Salamander") on a pilot program to deploy Salamander's advanced heating technology in Venezuela. The technology partnership between the JV Company and Salamander will be leveraged to evaluate and unlock prospective heavy oil resources in the assets of the JV Company.
About LNG Energy Group
The Company focuses on the acquisition and development of hydrocarbons production and exploration assets in Latin America. For more information, please visit www.lngenergygroup.com.
For more information please contact:
Angel Roa, Chief Financial Officer LNG Energy Group Corp.
Website: www.lngenergygroup.com
Email: [email protected]
Phone: (305) 464-6362
Find us on social media:
LinkedIn: https://www.linkedin.com/company/lng-energy-group-inc/
Instagram: @lngenergygroup
X: @LNGEnergyCorp
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. All statements other than statements of historical fact are forward-looking statements, and are based on expectations, estimates and projections as at the date of this news release that reflect the current views and/or expectations of management of LNG Energy Group with respect to performance, business and future events. Forward-looking statements in this press release include, but are not limited to, statements relating to: the execution and completion of the proposed Transaction; the finalization of definitive agreements; the total committed investment program of up to US$200 million; the development of the Venezuela assets; and the Company's anticipated growth and operational objectives. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied, including: the inability of the parties to negotiate and execute definitive agreements; failure to obtain required regulatory approvals (including those of OFAC, TSX Venture Exchange, and applicable Canadian securities commissions); adverse changes in the Venezuelan political, legal or regulatory environment; failure to complete due diligence to Fifth Ocean's satisfaction; and other factors described in the Company's public filings on SEDAR+. LNG Energy Group does not undertake any obligation to release publicly any revisions to forward-looking statements, except as required by applicable securities law.
SANCTIONS COMPLIANCE NOTE:
The proposed Transaction involves assets located in Venezuela. The parties have acknowledged that all activities in connection with the Transaction will be conducted in full compliance with applicable U.S. sanctions laws and regulations, including those administered by OFAC. The Company will only proceed with the activities in connection with the Venezuela assets in accordance with OFAC authorizations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Berkshire Hathaway ve 2. čtvrtletí odkoupila vlastní akcie za 4,5 miliardy USD, nejrychlejším tempem za několik let. Článek tvrdí, že její provozní byznys se obchoduje asi za 10,2násobek zisku za posledních 12 měsíců.
Berkshire Hathaway (BRKA -0.18%)(BRKB -0.19%) bought back $4.5 billion of its own stock in the second quarter, its most aggressive pace of buybacks in several years. Unlike many other companies that buy back stock, Berkshire can do so only when CEO Greg Abel and Chairman Warren Buffett agree that the stock is trading below its intrinsic value.
Are they right? Is Berkshire truly a cheap stock right now?
Of course, it's tough to do a full piece-by-piece analysis in a short article, but we can use the three main parts of Berkshire Hathaway's business to help determine if the stock is cheap or expensive.
Image source: Getty Images.
Berkshire: A sum of three parts As of this writing, Berkshire's market cap is about $1.09 trillion. If the sum of the parts is worth more than that, it's trading for less than its intrinsic value.
Thankfully, two of the three parts of the business are easy to value. At the end of the second quarter, Berkshire had $365.5 billion in cash and Treasuries on its balance sheet. And as I'm writing this, Berkshire's stock portfolio is worth about $360.5 billion. Subtracting these two numbers shows that Berkshire's operating businesses are being valued at about $364 billion.
Over the past four quarters, Berkshire has produced just over $48 billion in operating earnings. After subtracting investment income from the insurance business (which is mostly the interest earned on its cash), Berkshire's operating income was $35.8 billion.
This means that Berkshire's operating businesses are trading for about 10.2 times trailing earnings. That's a very low multiple. For context, the average stock in the S&P 500 trades for about 28 times earnings. The average energy company (a big part of Berkshire's business) trades for a mid-teen multiple, and the average railroad stock (Berkshire owns BNSF) trades for about 22 times earnings, just to name a few components.
Of course, there are many moving parts to consider, and not every sign points to a high valuation. For example, insurance companies are generally trading for a low double-digit earnings multiple right now, and Berkshire's GEICO has been underperforming its peers in recent years.
Having said that, there's a solid case to be made that Berkshire's intrinsic value is significantly higher than its current market value. Exactly how much higher is a tougher question to answer. If you were to ask 10 experienced stock analysts to calculate the intrinsic value of Berkshire's stock, you'd probably get 10 different answers. However, it's easy to see why Abel might have decided to step on the gas when it comes to buybacks, given the low value the market is assigning to its operating businesses.
Medtronic v 1Q fiskálního roku 2027 překonal odhady tržbami 9,76 mld. USD i očištěným EPS 1,45 USD a zvýšil celoroční výhled organického růstu tržeb i zisku na akcii. Akcie v předburzovní fázi přidávají 5,01 %.
Výrobce zdravotnických zařízení Medtronic zveřejnil výsledky za první kvartál fiskálního roku 2027, který skončil 31. července 2026. Tržby i očištěný zisk na akcii překonaly odhady trhu a společnost zároveň zvýšila celoroční výhled organického růstu tržeb i zisku na akcii.
Výsledky společnosti Medtronic (MDT) za 1Q FY 2027 1Q FY 2027 Konsensus 1Q FY2027 1Q FY 2026 Tržby (mld. USD) 9,76 9,54 8,54 Čistý zisk (mld. USD) 1,86 -- 1,63 Očištěný zisk na akcii (EPS, USD/akcie) 1,45 1,39 1,26 Výsledky za 1Q Tržby v prvním kvartále vzrostly meziročně o 13,7 % na 9,76 mld. USD, na organické bázi rovněž o 13,7 %. Do čísel se promítl navíc jeden fiskální týden, jehož přínos k organickému růstu firma odhaduje přibližně na 570 mil. USD.
Očištěná hrubá marže zaznamenala meziroční růst o 10 bazických bodů na 65,2 %. Trh projektoval 64,8 %.
Tržby Medtronicu v 1Q FY 2027 dle segmentů
(v mld. USD) Segment Tržby Konsenzus Meziroční změna Kardiovaskulární 3,93 3,78 +19,5 % Neurověda
2,68 2,66 +10,3 % Lékařsko-chirurgický
2,28 2,25 +10,0 % Diabetologie 0,84 0,82 +16,9 % Tahounem zůstal kardiovaskulární segment, v němž divize Cardiac Ablation Solutions vzrostla o 88 %, v USA dokonce o 139 %, a meziročně získala 9procentních bodů amerického tržního podílu. Cardiac Rhythm Management přidal 15 % a divize Cranial & Spinal Technologies 13 %. Z hlediska regionů rostly tržby v USA organicky o 15,8 % na 4,91 mld. USD, mimo USA o 11,6 % na 4,85 mld. USD.
Očištěná provozní marže dosáhla 23,7 % oproti 23,6 % před rokem, přičemž odhad trhu činil 23,8 %.
V průběhu kvartálu Medtronic dokončil akvizice společností Scientia Vascular a SPR Therapeutics. Zároveň oznámil strategickou investici a distribuční dohodu se společností Cornerstone Robotics týkající se systému Sentire na vybraných trzích mimo USA.
Výhled Společnost zvýšila celoroční výhled a pro fiskální rok 2027 nyní očekává:
Organický růst tržeb o 7,25 až 7,75 %, tedy o 50 bazických bodů více než dosavadních 6,75 až 7,25 %. Očištěný zisk na akcii v rozmezí 5,94 až 6,00 USD oproti předchozím 5,90 až 6,00 USD. Odhad Wall Street byl na úrovni 5,96 USD. Výhled zahrnuje vliv měnových kurzů na zisk na akcii v rozmezí neutrálního dopadu až 1% přínosu, u tržeb naopak negativní dopad 50 až 150 mil. USD.
Výhled také nadále zahrnuje diabetologický segment po celý fiskální rok 2027. Oddělení tohoto byznysu chce společnost dokončit ještě před koncem fiskálního roku a po jeho realizaci výhled aktualizuje.
Komentář vedení „Fiskální rok 2027 jsme zahájili silně. Důvěru nám nedodává pouze samotná síla tohoto kvartálu, ale především šíře výkonnosti napříč našimi obchodními jednotkami a rostoucí příspěvek novějších růstových platforem,“ uvedl generální ředitel Geoff Martha. „Naše realizační schopnost spolu s inovačním motorem nám umožňuje pomáhat většímu počtu pacientů a dosahovat udržitelného růstu. Síla našeho portfolia a připravovaných inovací nám dodává jistotu ohledně příležitostí, které máme před sebou.“
„Nadále cíleně investujeme do inovací, rozvoje portfolia a obchodní realizace, což podpoří udržitelnou dlouhodobou tvorbu hodnoty,“ uvedl finanční ředitel Thierry Piéton. „Kombinace silné provozní výkonnosti a disciplinovaného finančního řízení dostala tržby i očištěný zisk na akcii nad očekávání, což nám umožnilo zvýšit výhled pro fiskální rok 2027.“
Akcie Medtronic Akcie Medtronic (MDT) v předburzovní fázi obchodování posilují o 5,01 % na 95,19 USD.
Bio-Techne získala validaci SBTi pro své cíle snižování emisí Scope 1, 2 a 3. Emise Scope 1 a 2 meziročně klesly o 49 % a obnovitelné zdroje nyní tvoří 51 % spotřeby elektřiny.
Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the company's electricity consumption now comes from renewable sources First comprehensive Scope 3 emissions inventory completed , /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.
The SBTi validated Bio-Techne's targets to reduce absolute Scope 1 and 2 greenhouse gas emissions by 70% by fiscal year 2031 from a fiscal year 2025 baseline and to commit that 81% of suppliers by spend covering purchased goods and services, capital goods, upstream transportation and distribution and business travel will have science-based targets by fiscal year 2030.
Validation of the greenhouse gas reduction targets provides customers, suppliers and other stakeholders with independent confirmation that the Company's climate goals are aligned with recognized global standards and climate science.
"Our Science Based Targets validation and progress against those targets demonstrate Bio-Techne's commitment to growing responsibly," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "As we support scientific and diagnostic innovation around the world, we are also taking meaningful steps to reduce our environmental impact and strengthen sustainability across our operations and value chain."
Bio-Techne also expanded its use of renewable electricity during the year. The company transitioned its Minneapolis headquarters to 100% renewable electricity and began procuring renewable electricity for its St. Paul GMP facility. As a result, renewable sources now account for 51% of Bio-Techne's total electricity consumption.
ABOUT BIO-TECHNE
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.
CONTACT:
Corporate Communications
[email protected]
David Clair, Vice President
Investor Relations
[email protected]
Beam Therapeutics jmenovala Erica Fostera ředitelem pro komerční záležitosti. Povede komerční strategii firmy při přípravě možného uvedení risto-cel v roce 2027.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.
“Eric is an exceptional biopharmaceutical leader with a proven track record of building high-performing commercial organizations in specialty and rare disease markets,” said John Evans, chief executive officer of Beam Therapeutics. “His decades of commercial leadership are impressive, including spearheading the commercial success of multiple blockbuster rare disease franchises at Horizon Therapeutics during a period of significant growth prior to its acquisition by Amgen. As we prepare for the potential launch of risto-cel in 2027, Eric's experience building strong teams and culture, defining and executing clear commercial strategies, and leading through growth will be invaluable as we lay the foundation for Beam's next chapter and work to bring multiple precision genetic medicines to patients in the years ahead.”
Mr. Foster brings more than 25 years of commercial leadership experience across biotechnology and specialty pharmaceuticals and most recently served as chief commercial officer at Ardelyx. Prior to Ardelyx, Mr. Foster served as senior vice president and U.S. general manager at Amgen following the acquisition of Horizon Therapeutics in October 2023. At Horizon, he was senior vice president and general manager of the gout and ophthalmology business units, where he led operations for franchises that represented $2.75 billion in net sales revenue. Prior to his time at Horizon, from 2010 to 2021, Mr. Foster held roles of increasing responsibility in sales and marketing at GlaxoSmithKline across a variety of immunology and rare disease products, including serving as vice president of immunology marketing, senior global marketing director and field sales vice president. Mr. Foster began his career in sales and market access at Johnson & Johnson. Mr. Foster holds a Bachelor of Arts in Economics from the University of Georgia and a Master of Business Administration from Auburn University.
“I'm excited to join Beam at such an important moment in the company's evolution,” said Foster. “Beam has built one of the most innovative platforms and deepest pipelines in biotechnology, with the potential to redefine how serious genetic diseases are treated. I look forward to partnering with the talented team at Beam to build a leading commercial organization, establish the capabilities needed to support multiple potential launches and, ultimately, bring these transformative medicines to patients.”
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the timing and effective date of the appointment of Mr. Foster; the contributions Mr. Foster may make in his role with the company; the therapeutic applications and potential of our technology; the anticipated timing of potential product launches, including any potential launch of risto-cel; our plans to advance our programs; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; our ability to build and scale commercial infrastructure, including a sales and marketing organization, to support potential product launches; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Midstream společnosti v Permské pánvi budují novou plynovou a NGL infrastrukturu, protože do roku 2030 má přibýt 15,2 Bcf/d nové přepravní kapacity. Současné backlogy šesti firem už přesahují 160 miliard USD.
As noted last week, midstream MLPs and corporations broadly raised full-year financial guidance following a strong second quarter. Looking ahead, the sector’s growth runway is accelerating. Additional Permian natural gas takeaway capacity is prompting a wave of new gas processing and natural gas liquids (NGL) infrastructure as production grows. Meanwhile, surging liquefied natural gas (LNG) exports and power generation demand are driving record backlogs across the space.
Key Takeaways The arrival of critical natural gas pipeline capacity is alleviating longstanding constraints in the Permian. Over 15 billion cubic feet per day (Bcf/d) of new takeaway capacity is expected by 2030. To accommodate rising producer volumes and a gassier Permian production mix, midstream operators are sanctioning new gas processing plants and gathering systems. Surging electricity needs for data centers and advancing U.S. LNG export facilities continue to expand project backlogs. These now collectively exceed $160 billion for six names with significant natural gas infrastructure. Easing Permian Bottlenecks Unlock Further Capacity The Permian Basin is the nation’s largest oil-producing area and its second-largest natural gas-producing region. While long known for its oil output, the basin’s production mix is continuing to get gassier. Today, each barrel of Permian crude comes with 1.3 barrels equivalent of natural gas and NGLs (up from 1.0 in 2022). This is forcing midstream operators to aggressively expand processing and takeaway capacity to keep pace with rising volumes. The surge in associated natural gas production (i.e., natural gas produced from an oil well) has resulted in pipeline bottlenecks in the basin at times, with the latest constraint now alleviating.
New Pipelines Easing Permian Constraints Critical infrastructure relief began to arrive in the middle of this year. The June start-up of Kinder Morgan’s (KMI) 570 million cubic feet per day (MMcf/d) Gulf Coast Express Expansion served as the basin’s first incremental relief valve. This also coincides with the West Texas (Waha) natural gas price benchmark switching into positive territory after months of negative trading. For context, the Permian basin produced 28.7 billion cubic feet per day (Bcf/d) of natural gas in 2025.
Additional takeaway capacity is imminent. Recent updates include Energy Transfer’s (ET) 1.5 Bcf/d Hugh Brinson natural gas pipeline entering commercial service earlier than expected and 2.5 Bcf/d joint venture Blackcomb pipeline commissioning in July. The added natural gas capacity from these two projects creates a positive runway for continued production growth from the basin into 2027 and beyond. Meanwhile, more projects are already under construction to enter service over the next few years.
Most recently, a consortium led by WhiteWater Midstream sanctioned the Solitude Pipeline System, which will route from the Permian to Katy, Texas. The system will consist of two 2.25-Bcf/d pipelines, with the first slated for late 2029 and the second coming on in 2030. The natural gas pipelines shown above will add approximately 15.2 Bcf/d of collective takeaway capacity out of the Permian by 2030. This infrastructure wave provides critical egress, enabling continued basin production growth even as associated natural gas volumes rise.
Permian Processing Accelerates to Meet Volume Growth With natural gas takeaway constraints in the Permian easing, midstream operators are sanctioning new processing plants, fractionators (processing facilities for NGLs), and gathering expansions to accommodate rising producer volumes. As a result, capital spending guidance was raised or tightened by several operators, including EPD, ET, MPLX (MPLX), Plains All American (PAA), and Kinetik (KNTK).
Mixed NGLs are produced alongside crude oil and raw natural gas. Before these liquids can reach end markets, they must be separated from natural gas, transported via pipeline, and fractionated into individual products like ethane, propane, and butane. These products have applications in heating, fuel blending and as feedstocks for plastics. NGLs require dedicated midstream infrastructure across the entire value chain and often command premium fees due to their complexity.
NGL Growth Projects To capture the expected volume growth in Permian NGLs, midstream operators sanctioned a number of major organic growth projects:
Targa Resources (TRGP) announced new 20-year fee-based agreements with ExxonMobil (XOM) and sanctioned three new natural gas processing plants in the Delaware Basin with an aggregate capacity of ~825 MMcf/d, expected in service in 1H28. EPD announced a new 300-MMcf/d gas processing plant in the Delaware Basin, a 300-MMcf/d plant in the Midland Basin, and a new 150 thousand barrel per day (MBpd) NGL fractionator at Mont Belvieu. ONEOK (OKE) upsized the planned Bighorn processing plant in the Delaware Basin to 400 MMcf/d, citing strong producer activity, and reached the 80% contracting target for its 200-MBpd share of the planned joint venture liquefied petroleum gas (LPG, a subset of NGLs) export terminal. KNTK announced the gas processing plant Kings Landing II, expanding system processing capacity by 300 MMcf/d, and authorized procurement of long-lead equipment for the next processing expansion. PAA announced the build-out of Permian gathering systems to service an additional 120,000 dedicated acres, bringing its total dedicated Permian acreage to ~5.1 million acres. In Canada, midstream operators are also expanding infrastructure to support NGL logistics and regional petrochemical demand. Keyera (KEY CN) recently sanctioned the Alberta Corridor Export (ACE) rail terminal project, a facility designed to load unit trains and significantly boost exports of Canadian LPG.
Similarly, Pembina Pipeline (PPL CN) recently sanctioned the $570 million Heartland Extraction Plant (HEP), a new NGL extraction facility. The announcement was accompanied by an amended long-term agreement to supply Dow (DOW)‘s expanding petrochemical operations, increasing Pembina’s total contracted ethane volumes to Dow by 15% to just over 57 MBpd.
Natural Gas Tailwinds Continue to Support Robust Backlogs Long-term natural gas demand drivers, anchored by new LNG export infrastructure and rising power needs, continue to expand midstream project backlogs across North America. Collectively, disclosed project backlogs for six midstream companies with significant natural gas infrastructure now exceed $160 billion. This provides multi-year visibility for fee-based EBITDA growth.
Most notably on the LNG side, Enbridge (ENB CN) and MPLX sanctioned the joint venture 2.6 Bcf/d Bay Runner Twin Pipeline, which will supply natural gas to NEXT’s Rio Grande LNG facility under long-term take-or-pay agreements.
Power Generation Projects Natural gas demand for power generation facilities is supporting a number of new projects announced alongside second-quarter earnings updates:
TC Energy (TRP CN) sanctioned the $300 million Central Virginia Capacity project (Columbia Gas) and $100 million Clark project (Columbia Gulf) to serve natural gas-fired power generation and data center demand. DT Midstream (DTM) sanctioned three new organic growth projects, including a 200-MMcf/d Haynesville system expansion (LEAP Phase 5) and commercialized a new 380 MMcf/d interconnect on NEXUS to supply natural gas power generation for an Ohio data center. Williams (WMB) announced two new expansion projects tied to the recently acquired Momentum Midstream footprint, upsized Transco’s Power Express to 800 MMcf/d, and announced a 7-mile extension of its Woodside LNG-anchored Line 200 pipeline to serve Louisiana power demand. OKE secured a natural gas supply agreement for 1 gigawatt (GW) of power plant demand and noted late-stage commercial discussions to supply AI data centers. Antero Midstream (AM) is evaluating a backlog of 15 additional projects in West Virginia, primarily related to power generation and data centers, representing “several billion dollars” of potential opportunities. The multi-billion-dollar backlogs for natural gas infrastructure names, spanning both projects under construction and future projects, support a multi-year runway for highly visible, fee-based EBITDA growth. As a result, many midstream names focused on these opportunity sets have been able to raise their long-term guidance.
Bottom Line Natural gas and NGL infrastructure momentum shows no signs of slowing as operators execute on massive, multi-billion-dollar backlogs tied to rising Permian volumes, expanding LNG exports, and increased power demand. Backed by a strong outlook and durable fee-based cash flow growth, midstream operators are well-equipped to fund these stepped-up expansion programs while maintaining solid financial flexibility.
For the latest insights on how energy infrastructure can provide reliable yield and defensiveness amid market uncertainty, watch the replay of our recent 30-minute webcast, “Navigating Macro Volatility with Energy Infrastructure.”
Looking for midstream insights in your inbox? Subscribe here to keep a pulse on midstream investing through our weekly updates.
Related Research: Strong Midstream 2Q26 Earnings Boost Full-Year Outlook
Midstream: Robust Gas Backlogs Drive Growth Visibility
Surging U.S. Power Needs Drive Gas Infrastructure Opportunity
U.S. LNG Exports Surge Despite 4Q25 Headwinds
Permian Powers Midstream Growth From Well to Water
Midstream Prepares for More Permian Natural Gas
For more news, information, and analysis, visit the Energy Infrastructure Content Hub.
Apple varuje, že dražší paměťové čipy stlačí marže i prodeje iPhonů i po tomto čtvrtletí. CFO uvedl, že marže za zářijové čtvrtletí klesnou na 46,5 % z 48,1 % v červnovém čtvrtletí (po vyloučení celních benefitů).
On his last earnings call as Apple (AAPL -0.89%) CEO, Tim Cook said his company is facing a unique challenge due to a shortage of memory chips for its devices.
Data centers are gobbling up available memory, leaving Apple and its peers paying more for memory than in the past, and causing shortages. Cook said he anticipates "market pricing for memory continuing to increase, which could drive an increasing impact on our business."
Importantly, management said rising memory costs could affect iPhone sales and reduce the company's margins beyond the current quarter.
Cook's warning came as new Apple CEO John Ternus just took the helm at the company. Here's what Apple shareholders need to know about the memory shortage's impact on Apple's margins.
Incoming Apple CEO John Ternus. Image source: Apple.
Cook said on the third-quarter earnings call that Apple has consistently anticipated paying more for memory in each subsequent quarter. And that's exactly what's happened. Cook noted:
"As I alluded to last quarter, we expected to pay significantly more in the June quarter than the March quarter, and that is what happened.... For September, we expect to pay even higher memory costs..."
While Apple has the benefit of pre-purchasing memory at a lower cost, Cook said this benefit is declining over time and will continue to do so beyond the September quarter because prices keep rising.
Apple raised prices on its Macs in June and is widely expected to increase the prices of some of its new iPhones when they debut on Sept. 9. Price hikes help offset some of the rising memory costs, but they're not enough to erase the damage.
And Apple's management was clear that its device margins would fall.
Premium Feature
Moneyball Superscore
88/100
Today's Change
(
-0.89
%) $
-2.85
Current Price
$
316.85
Apple's margins will drop (at least temporarily) under Ternus Apple CFO Kevan Parekh said on the call that the company's margins will be 46.5% for the September quarter, down from 48.1% in the June quarter (excluding tariff benefits). And he specifically cited memory as the reason for the decline, noting that the decrease is "really driven by memory."
This decline comes just as John Ternus is taking over for Cook. So what might Ternus do about the falling margins?
Apple has reportedly already tested DRAM memory chips from the Chinese company CXMT. The idea behind the move is that Apple could use memory from this supplier for Apple devices sold in China. The Financial Times has also reported that Apple is lobbying the U.S. government to allow broader use of CXMT's memory processors outside of China.
But that likely won't be the fix Apple needs. CXMT has already reached its annual memory production capacity, according to the Wall Street Journal.
For now, it looks as if Apple's margins will decline slightly under Ternus, and the company doesn't have a permanent fix -- even with raising device prices.
Samsung, SK Hynix, and Micron Technology are the world's three largest memory companies -- accounting for about 94% of the DRAM memory market -- and all are all Apple suppliers. And management at SK Hynix and Micron have said the current memory crunch could last through 2027 or even 2030.
All of which means that Apple will likely be battling to regain its margins early in Ternus' tenure -- at least until the company can find the right mix of price increases and memory supply.
Tesla v pondělí posílila o 5,5 % před čtvrtečním představením Cybercabu, které má ukázat konkrétní pokrok v autonomii. Investoři sledují, zda obhájí valuaci 1,45 bilionu USD.
Buy NASDAQ:TSLA. The stock is already pricing a positive autonomy step; the catalyst is Thursday’s Cybercab launch. The thesis is that Tesla can convert “demo” into measurable progress—clearer deployment plan, early fleet utilization targets, and credible cost-per-mile narrative—supporting a re-rating despite low current robotaxi revenue.
Key Risk: Cybercab is another showcase with vague timelines (low deployment volumes and no clear path to unsupervised operations), so the market decides the autonomy premium is unjustified.
TSLA sell if robotaxi economics disappoint
Sell NASDAQ:TSLA if Thursday fails to provide concrete autonomy milestones. The valuation depends on robotaxi scaling; if Tesla can’t outline near-term geographic rollout, autonomous-ride economics, and progress toward removing safety monitors, the market will compress the autonomy multiple quickly.
Key Risk: Tesla gives no credible numbers on fleet scale, autonomous miles, or ride economics—execution risk overwhelms the technology story.
Tesla stock NASDAQ:TSLA surged 5.5% on Monday as investors positioned for a key autonomy event, putting its $1.45 trillion valuation back under scrutiny.
The stock closed at $367.95 on August 31, extending its August gain to about 18% as the broader market slipped. Tesla remains down roughly 18% in 2026.
Attention now turns to Thursday’s Cybercab launch event in Austin. The purpose-built autonomous vehicle has no steering wheel or pedals and is designed to become central to Tesla’s robotaxi network.
The gap between Tesla’s current robotaxi revenue and the value investors assign to the business is striking.
Morningstar senior equity analyst Seth Goldstein estimated on August 18 that robotaxis generated well under 0.5% of Tesla’s total revenue in 2025, yet account for more than 30% of Morningstar’s $450-per-share fair value estimate.
Goldstein called putting Cybercab into Tesla’s fleet “a positive step forward” for its autonomous-driving software.
Morningstar expects the vehicles to have relatively low operating costs and believes the service could eventually generate strong margins.
But that also raises the bar for Thursday, as investors already assign significant value to profits that barely exist today.
A credible launch therefore needs more than another futuristic demonstration.
Deployment timing, autonomous miles, fleet utilisation, operating costs and the pace at which safety monitors can be removed are likely to matter more to the valuation debate.
The bullish case rests on Tesla turning those technological advantages into a large commercial network.
New Street Research analyst Peter Vogel reiterated a Buy rating and $600 price target. He argues Tesla has three major robotaxi advantages: low vehicle costs, a flexible supply model and a huge existing fleet.
Vogel also sees Tesla’s vertically integrated, camera-based approach producing structurally lower costs per mile than rival systems.
New Street estimates robotaxis could eventually generate more than $40 billion in revenue and about $15 billion in EBIT by 2030.
Wedbush analyst Dan Ives is more aggressive.
TipRanks reported that Ives sees Tesla exceeding a $2 trillion market value over the coming year, with a bull case approaching $3 trillion by the end of 2026 if autonomy and robotics scale successfully.
His argument makes execution the bridge between Tesla’s current valuation and another major re-rating.
Cybercab must become a scalable commercial service, not simply another vehicle Tesla can manufacture.
The risk is that Tesla’s autonomy rollout has repeatedly taken longer than some of Elon Musk’s earlier forecasts.
Barclays analyst Dan Levy remains cautious. The analyst pointed to slower-than-expected progress in Tesla’s robotaxi ambitions and the danger that enthusiasm around Cybercab could run ahead of execution.
That matters because Tesla’s conventional automotive business alone does not explain the valuation investors see across investment platforms.
Investors are paying a substantial premium for autonomy, artificial intelligence and robotics, making delays more consequential.
Thursday does not need to prove Cybercab can immediately become profitable. But investors will want clearer answers on deployment volumes, geographic expansion, unsupervised operations and autonomous-ride economics.
NVIDIA rozšiřuje NVLink na trhu zakázkových AI čipů a podle analytika tím přímo zvyšuje tlak na Broadcom. Prvním zveřejněným zákazníkem je Amazon.com Inc.’s Annapurna Labs.
NVIDIA Corp. (NASDAQ:NVDA) stock fell more than 1% in Tuesday’s premarket trading as investors pulled back from large-cap technology stocks. Nasdaq futures dropped 1.02%, while S&P 500 futures fell 0.59%.
The broader market weakness came as analysts assessed NVIDIA’s growing push into the custom artificial intelligence chip market. That strategy could open a new growth channel for NVIDIA while increasing competitive pressure on Broadcom.
NVIDIA’s NVHBM Push Threatens Broadcom’s AI Chip Position, Analyst SaysNVIDIA is expanding deeper into the custom artificial intelligence chip market with NVHBM, according to Counterpoint Research analyst Neil Shah.
The technology could challenge Broadcom Inc. (NASDAQ:AVGO) while strengthening NVIDIA’s influence over AI infrastructure.
NVHBM moves the memory controller from the accelerator chip into the base die of a high-bandwidth memory stack. It also replaces the standard JEDEC memory bus with NVIDIA’s proprietary die-to-die connection.
Shah said the approach gives NVIDIA control over the memory controller, interface and link protocol. Memory suppliers would manufacture the base die based on NVIDIA’s design.
NVIDIA Expands Beyond GPUsThe strategy could allow NVIDIA to sell its networking fabric, rack architecture, software and memory subsystem to companies developing custom accelerators. NVIDIA would not need to design the accelerator itself.
Amazon.com Inc.’s (NASDAQ:AMZN) Annapurna Labs is the first disclosed customer. It plans to use NVHBM with its Trainium4 AI chip.
MediaTek also adopted NVIDIA’s NVLink Fusion platform. Shah said this gives NVIDIA another channel for reaching custom chip customers.
However, the analyst questioned some of NVIDIA’s performance claims. The company compared NVHBM with HBM4E, which is not yet shipping, and did not disclose its full testing baseline. Shah said only the claimed 67% reduction in physical interface area can be checked using available pin-count data.
Broadcom Faces New CompetitionShah said NVHBM places NVIDIA directly in a market served by Broadcom and Marvell Technology Inc. (NASDAQ:MRVL).
Broadcom could benefit from wider adoption of custom AI chips. Still, it lacks a comparable base-die offering, according to the analyst.
Marvell outlined a similar architecture in December 2024 and has joined NVLink Fusion. That leaves Broadcom as the only major custom chip design company without a direct NVIDIA partnership, Shah said.
NVIDIA Technical Analysis And Analyst OutlookNVIDIA remains in a longer-term uptrend despite the early decline. The stock trades 4.5% above its 50-day simple moving average of $208.62. It is also 11.3% above its 200-day SMA of $195.96.
However, NVIDIA trades about 0.3% below its 20-day SMA of $218.75. That level could influence the stock’s near-term direction.
The relative strength index stands at 54.25. This neutral reading suggests the stock is consolidating. It is neither overbought nor oversold.
The moving-average structure remains bullish. The 20-day SMA sits above the 50-day average. Meanwhile, the 50-day SMA remains above the 200-day average.
Key resistance stands near $228. A stronger rally could put the 52-week high of $236.54 back in focus. Support sits near the 200-day SMA, followed by the $190 level.
The stock trades at 27.9 times earnings. That valuation reflects high expectations for continued growth. NVIDIA carries a consensus Buy rating and an average price forecast of $349.15.
Citigroup and Mizuho raised their price forecasts to $315 on Aug. 27. JPMorgan increased its forecast to $320. Citigroup maintained a Buy rating, Mizuho kept an Outperform rating and JPMorgan maintained an Overweight rating.
NVDA Price ActionNVIDIA shares fell 1.35% to $217.80 in Tuesday’s premarket session, according to Benzinga Pro.
Target zvýšil celoroční výhled a čeká růst čistých tržeb kolem 5 %, tedy o celý procentní bod více než dříve. Akcie tak podle firmy zůstávají podhodnocené.
Investors have written off Target (TGT -1.41%) over the last few years as sales stumbled and reputational damage has taken its toll. But the retail giant's comeback is well underway, and there is one reason in particular that Target is worth a second look this month.
What's got investors talking is that Target raised its full-year outlook, and the comeback is in full swing as we head into the holiday shopping season. The guidance raise is significant for a few reasons.
First, it shows that the company is confident its turnaround is not only taking hold, but picking up steam. Second, Target anticipates net sales growth of around 5%, which is an entire percentage point higher than the previous guidance. Lastly, Target is trading at a very reasonable price right now, especially compared to its longer-term history.
Image source: The Motley Fool.
What Target can't afford at the moment is more missteps. A highly controversial Halloween costume was recently pulled from shelves, leading to more calls to boycott. The easily avoidable mistakes need to stop if Target wants to bring back customers for good.
Ultimately, Target's turnaround is for real, and you can see it in its latest numbers. The stock hasn't quite caught up yet, which is why Target is worth a closer look this month.
Premium Feature
Moneyball Superscore
65/100
Today's Change
(
-1.41
%) $
-2.30
Current Price
$
160.88
Target's stock has risen about 65% thus far in 2026, but is still down more than 34% over the past five years. As we approach the holiday shopping season, Target has a real opportunity to climb back to its previous peak. It just can't afford any more face-palm trip-ups.
Catie Hogan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Target. The Motley Fool has a disclosure policy.
Odbory Micronu na Tchaj-wanu hrozí stávkou, pokud firma nezmění bonusový systém a nepropojí odměny více se ziskem. Více než 80 % členů v srpnovém průzkumu stávku podpořilo.
Micron Technology's (MU.O) labour unions in Taiwan said on Tuesday they were moving towards possible strike action unless the U.S. memory-chip maker overhauls its bonus system and shares more of its profits with employees.
The unions, representing Micron workers in Taoyuan and Taichung, said in a written response to Reuters that they had nearly 10,000 members among Micron's roughly 15,000 employees in the two cities.
More than 80% of members who took part in an internal online survey in August backed strike action, they said.
Micron's Taiwan office said in response to a request for comment that this year's performance-bonus payout would be the highest in the company's history.
It said it would continue to engage with employees through existing channels while respecting applicable legal processes.
The strike threat comes as booming demand for memory chips used in artificial intelligence hardware has tightened global supply and lifted profits across the sector.
Micron, the world's third-largest memory-chip maker, reported record revenue of $41.46 billion and net income of $28.24 billion for its fiscal third quarter ended May 28, as demand for its products surged. The company's market value was about $1.10 trillion on Tuesday.
A strike at Micron would be highly disruptive because Taiwan is the company's largest manufacturing base, according to authorities in Taipei. They say Micron has invested NT$1.4 trillion ($43.9 billion) in the island and produces DRAM and high-bandwidth memory chips there.
The government-run Central Taiwan Science Park administration said last month it was closely monitoring the dispute and had assigned staff to help facilitate contacts between Micron and the unions.
It said a strike could affect workers' livelihoods, Micron's operations and potentially Taiwan's semiconductor supply chain and wider economy, adding that it could launch labour-management negotiations or mediation if needed.
The dispute echoes a showdown at Samsung Electronics (005930.KS) in South Korea, where a planned 18-day strike involving as many as 48,000 union members was called off in May after last-minute negotiations.
That deal created a special bonus pool worth 10.5% of the chip division's operating profit, subject to profitability targets.
Micron's Taiwanese unions said profit-sharing arrangements at Samsung and SK Hynix (000660.KS) had widened the gap between Micron workers and their South Korean counterparts.
UNIONS SEEK PROFIT-LINKED BONUSES
For fiscal 2026, the unions are seeking an additional one-off bonus payment, arguing that Micron's existing Incentive Pay Plan (IPP) does not adequately reflect the company's profitability.
The unions said their proposal would amount to about 83 months' salary for each Taiwan-based employee.
From fiscal 2027, they want the IPP replaced with a system that allocates 15% of operating profit to bonuses and distributes payments quarterly rather than annually.
Micron's IPP determines annual bonuses using company and individual performance measures. The unions said the company had not fully explained how its company-performance metric was calculated and argued that it appeared to track revenue growth more closely than profit.
The unions said Micron had indicated it would keep the existing IPP for this year's bonus payments while delaying negotiations.
Micron said its compensation structure differs from the profit-sharing model sought by the unions. According to the company, employee pay packages include base salary, annual performance incentives, operational bonuses and equity programmes, including stock-purchase and restricted-stock plans.
The dispute comes as Taiwan seeks to reinforce its reputation as a reliable hub for global chip production.
President Lai Ching-te said on Tuesday that the island's semiconductor sector had been built through specialisation and long-term cooperation, and that Taiwan had consistently supplied the global market and honoured its commitments.
Micron uvedl, že AI strukturálně změnila odvětví pamětí a že nabídka se s poptávkou nemusí dorovnat ještě několik let. Firma navíc uzavřela 16 Strategic Customer Agreements s lepší viditelností budoucích výnosů.
Micron Technology (MU +2.77%) has been delivering remarkable numbers so far in 2026. Revenue reacheda record $41.5 billion in the quarter ended May 28, up from $9.3 billion a year earlier. Net income soared to $28.2 billion, while gross margin climbed to 84.6%.
Those numbers (and others in its report) were impressive. But investors are generally focused on the future of the companies they invest in and are already looking for clues to what Micron will report next. Those clues will likely come in Micron's upcoming late-September earnings release.
Three sentences from management's last earnings presentation offer a possible glimpse into the company's (and the stock's) future. Taken together, they suggest that AI may have permanently changed the memory industry, supply could remain tight for years, and Micron is building a more predictable business model.
Image source: Getty Images.
Sentence No. 1: AI has structurally changed the industry Micron's management made a striking statement in its fiscal 2026 Q3 report: "The proliferation of AI has structurally transformed the memory industry."
The most important word here is structurally. Micron isn't saying AI has simply created a temporary spike in memory demand. It's saying AI has changed the underlying industry.
That distinction matters. For decades, investors have treated Micron as a highly cyclical memory company. Demand rises, memory prices increase, profits surge, manufacturers add capacity, supply catches up, and the downturn portion of the cycle begins.
But AI could change the economics. Modern AI systems require enormous amounts of memory bandwidth and capacity. And the opportunity may extend beyond today's AI training systems. AI-enabled features are likely to spread into smartphones, PCs, vehicles, industrial applications, and robotics.
If that happens, Micron won't simply sell more memory during an AI boom. It could participate in a much larger and more durable market over time. That's a potentially enormous difference.
Premium Feature
Moneyball Superscore
91/100
Today's Change
(
2.77
%) $
25.87
Current Price
$
958.73
Sentence No. 2: Supply may not catch up for years The second statement may matter even more for Micron's earnings:
"Even as we expect industry supply to improve gradually in 2028, we currently do not have line of sight as to when memory supply will be able to catch up with increasing demand."
That's a remarkable statement from a memory manufacturer. Micron expects supply to improve. But it still cannot see when supply will catch up with demand.
That matters because supply and demand determine the industry's pricing. When customers want more memory than manufacturers can provide, suppliers gain pricing power.
That dynamic helps explain Micron's extraordinary profitability today. Its gross margin surged from 38% a year ago to 85% in fiscal 2026 Q3. If demand continues to outpace supply for several more years, Micron could maintain strong pricing and profits for longer than investors expect.
But there is an important caveat. This is management's outlook, not a guarantee. Micron itself is investing heavily to increase production, and its competitors are doing the same. The company has also raised its planned U.S. investment to more than $250 billion through 2035.
Eventually, more supply will arrive. The question is whether demand will grow even faster over time.
Sentence No. 3: Micron is changing the way it sells memory The third sentence may prove the most important over the long term.
Micron announced that it had completed 16 Strategic Customer Agreements, or SCAs, and said they could fundamentally transform its business model.
Why does that matter? Because Micron is trying to make its future demand more visible.
The agreements provide customers with committed access to memory, while giving Micron greater visibility into future volumes and pricing. Micron says the agreements generally use take-or-pay commitments, with fixed pricing or pricing bands for many products.
That is a meaningful change for a cyclical industry. Historically, investors had to make educated guesses about how much memory customers would need, what prices would look like, and how much capacity Micron should build.
These agreements can give Micron much more information before it commits billions of dollars to new capacity. They could also reduce some of the volatility that has historically defined the memory business.
While that doesn't eliminate the memory cycle, it could make the cycle less painful.
Put the three sentences together. The first statement says AI has changed the industry's demand structure. The second says supply may remain behind demand for years. The third says Micron is securing more of its future business through long-term customer commitments.
Put them together, and you get a potentially powerful combination: More demand. Limited supply. Greater revenue visibility.
That's very different from the traditional memory industry. And it could have an important implication for Micron's valuation, since investors generally pay more for earnings they believe will continue.
What does it mean for investors? The most important part of Micron's last earnings presentation wasn't its record revenue. It was what management said about the future, particularly the three statements above. None of these developments guarantees that Micron stock will continue rising. But together, they point toward something potentially much bigger:
Micron may be becoming a better business over time.
For decades, investors knew Micron primarily as a cyclical memory producer. The next few years could determine whether AI turns it into something more valuable: a critical infrastructure supplier with stronger demand visibility, greater pricing power, and a more durable earnings base.
If that transformation succeeds, Micron stock could sustain its rally into the future.
eDreams ODIGEO oznámila výsledky nad odhady trhu a zvýšila počet předplatitelů Prime na 8,1 milionu. Upravený EBITDA dosáhl 28,9 milionu EUR a Net Income 0,2 milionu EUR.
BARCELONA, Spain--(BUSINESS WIRE)--eDreams ODIGEO (the "Company" or "eDO") (BME: EDR) (OTC: EDDRF), the world's leading travel subscription platform, today reported results for the first quarter of fiscal year 2027, the three months ended 30 June 2026. Performance was ahead of market estimates just as eDO entered the peak investment year of its multi-year roadmap. Set out in November 2025, this strategy is turning the business into a truly multi-product, global and diversified travel subscription platform servicing 13 million subscribers by March 2030.
Prime, eDO's subscription business, remained the main engine of growth. It added 173,000 net members in the quarter to reach 8.1 million, an 8% increase year-on-year, and now generates nine out of every ten euros of the Company's Cash Marginal Profit and 77% of its revenues3. Prime revenues grew 1% to €128.4 million, with total revenues at €165.5 million4.
The quarter delivered against plan. The key growth drivers in the roadmap, geographic and product expansion, are showing encouraging progress already contributing in the period. Revenues from markets outside eDO's core European base grew 5%, lifting their share of the total to 27% from 24% a year earlier.
Rail, the most recent vertical eDO has entered, is seeing pleasing adoption in line with plan. In Spain, the Company's most advanced rollout and one of Europe's most liberalised rail markets, rail already accounts for a double-digit share of new Prime members in this market. Adoption will vary as rollout maturity and deregulation differ across Europe, and eDO's long-term guidance, reaffirmed today, already assumes this.
Adjusted EBITDA of €28.9 million and Cash EBITDA of €23.0 million were both ahead of market estimates and consistent with the investment phase financials guided in November 2025. The difference between the two measures reflects the move from single upfront subscription payment to monthly installments. This is a temporary effect on when cash is collected, not on what is earned: the subscription remains a twelve-month commitment at the same price and unlocks greater customer lifetime value, lowering the barrier to joining Prime, and fitting the lower-ticket products eDO is expanding into. At €5.8 million in the quarter against €10.2 million a year earlier, the impact of the change is reducing rapidly. Even with these planned expansion investments, eDO remained profitable, reporting Net Income of €0.2 million and Adjusted Net Income of €4.7 million.
eDO is funding its growth phase from its own resources. Cash and cash equivalents closed at €73.0 million against €51.3 million a year earlier, net financial debt was €14.6 million lower year-on-year, and total liquidity stood at €237.1 million.
That same cash generation allows eDO to continue returning capital to shareholders while investing in growth. €5.3 million was deployed in the quarter, taking repurchases to €38 million since October 2025, with €62 million still committed through September 2027, a further 11% of market capitalisation5. Nearly 15 million shares, 12.6% of share capital, have been cancelled, with up to 9 million more authorised through July 2027: a growing profit pool across a contracting share base.
A year of guided investment for accelerated long-term growth and enhanced shareholder returns
Prime began as a flight-led proposition in a handful of European markets. It is now an AI-led, market leading subscription proposition being extended across the whole of travel, entering new adjacent verticals and a widening set of geographies.
In a subscription business, the cost of acquiring a member is incurred upfront while the revenue is earned across the membership and beyond. Fiscal year 2027 is carrying the bulk of the spending behind the March 2030 targets. As guided in late 2025, eDO is deliberately accepting higher acquisition costs and a short-term trade-off in profitability this year, to unlock significantly greater long-term value from April 2027 onwards.
The roadmap sets a clear trajectory from here. In the current year eDO expects 8.5 million Prime members and 600,000 net additions, with €167.0 million of Adjusted EBITDA before investments and €115.0 million of Cash EBITDA after, and expects to deliver year-on-year Cash EBITDA growth from the fourth quarter this year. Between April 2027 and March 2030 it expects record net additions of 1.5 to 2 million members a year, reaching 13 million Prime members and more than €270 million in Cash EBITDA, a compound annual growth rate of 33% from the current year.
Dana Dunne, Chief Executive Officer at eDreams ODIGEO said: "In November 2025, we said we would invest this year to unlock substantial long-term growth, and we are delivering exactly, coming in ahead of expectations. The underlying business is growing: more subscribers, in more geographies, adopting an expanded travel subscription offering, which de-risks and diversifies the business. This is what we promised we would do, and this is exactly what we are delivering.
“Our results reflect a deliberate, announced and time-bound investment phase, and we are on track to deliver year-on-year growth in profitability within two quarters. Conviction in our roadmap, 13 million Prime members and more than €270 million in Cash EBITDA by March 2030, is strengthened by this early delivery, and we continue to return capital to shareholders while we build the foundations for the growth ahead”.
-ENDS-
About eDreams ODIGEO
eDreams ODIGEO is the world’s leading travel subscription platform and one of the largest e-commerce businesses in Europe. Under its four renowned online travel agency brands – eDreams, GO Voyages, Opodo, Travellink, and the metasearch engine Liligo – it serves millions of customers every year across 44 markets. Listed on the Spanish Stock Market, eDreams ODIGEO works with nearly 700 airlines. The business launched Prime, the first subscription product in the travel sector which has topped over 8.1 million members since launching in 2017. The brand offers the best quality products in regular flights, low-cost airlines, hotels, dynamic packages, car rental and travel insurance to make travel easier, more accessible, and better value for consumers across the globe.
1 Based on Cash EBITDA.
2 Based on Revenue Margin.
3 Based on Cash Revenue Margin.
4 Based on Revenue Margin.
5 As of June 30th
Verisk odhaduje průměrné roční pojištěné katastrofické ztráty na 171 miliard USD, tedy o 19 miliard více než před rokem. I bez hurikánů v USA zůstaly ztráty už šestý rok nad hranicí 100 miliard USD.
Average annual insured catastrophe losses increased by approximately $19 billion in a year, the highest estimate Verisk has reported to dateDespite a season with no U.S. hurricane landfalls, estimated losses exceeded $100 billion for a sixth consecutive yearExposure growth, rising reconstruction costs and continued development in catastrophe-prone areas are pushing potential losses higher, regardless of weather patterns in any single year Jersey City, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- The catastrophe modeling business unit of Verisk (Nasdaq: VRSK), a leading data analytics and technology provider to the global insurance industry, today released Verisk's 2026 Global Modeled Catastrophe Losses Report. The annual report calculates that the insurance industry should be prepared to withstand $171 billion in insured catastrophe losses on average in a given year, up $19 billion from a year ago, and the highest estimate Verisk has reported to date. The industry’s loss benchmark increased even after a year with no U.S. hurricane landfalls for the first time in a decade, and it reflects continued growth in property values and insured values worldwide.
“A quiet hurricane season can lead markets to respond as if risk has eased: rates soften, insurers keep more risk on their own books, and more capital competes to write new business,” said Rob Newbold, president of Verisk Catastrophe and Risk Solutions. “But 2025 reminds us that the underlying risk landscape has changed and years without significant losses from U.S. hurricane activity no longer signal a quieter catastrophe environment.”
For the sixth straight year, global insured catastrophe losses exceeded $100 billion — a result driven not by severity perils like earthquakes and hurricanes, but by record-setting wildfires and significant severe thunderstorm activity, which produces widespread hail, wind and tornado damage across many communities rather than a single catastrophic event.
“A more dynamic risk environment underscores how catastrophe models help insurers maintain underwriting discipline and make informed pricing, capital allocation and risk transfer decisions based on the full range of risk, not just the outcome of a single season,” Newbold added.
Understanding Verisk's $171 Billion Loss Benchmark
The report’s headline figure is Verisk’s global insured average annual loss, or AAL: a modeled, long-term estimate of catastrophe risk derived from simulations across the company’s global suite of models. It is not a prediction of losses in 2026 or in any other individual year; rather, it serves as a benchmark insurers can use to evaluate potential losses across a wide range of events, perils and regions.
Several additional insights help put the number into context:
The United States accounts for the majority of modeled insured catastrophe risk. Of the $171 billion global insured AAL, $117 billion (68 percent) is attributed to the U.S. Severe thunderstorm accounts for 40 percent of modeled insured catastrophe risk, more than any other peril. It remains the largest contributor to Verisk's global insured AAL, ahead of tropical cyclone (27 percent), earthquake (10 percent), winter storm (9 percent), flood (7 percent) and wildfire (6 percent). The pattern held in 2025, when frequency perils, rather than a single hurricane, drove industry losses. A severe catastrophe year could generate losses nearly three times higher than the global insured AAL. The report also examines increasingly severe but plausible loss scenarios: At the 100-year return period – commonly used in the industry to describe a scenario with a 1 percent annual likelihood – modeled aggregate insured losses reach $477 billion. At the 250-year return period, losses reach $606 billion. Since Verisk first published this report in 2012, the estimated global insured AAL has nearly tripled, rising from $59 billion to $171 billion. The original 2012 figure was expressed in 2012 dollars. The change also reflects Verisk’s investment in expanding model coverage to more than 20 additional countries and regions, advances in science, data and modeling methods, updates to Verisk’s view of risk, and growth in insured exposure.
What's Driving Higher Losses Beyond the Hazard
Catastrophe losses are shaped by more than the number or severity of storms, wildfires or earthquakes in a given year. Several long-term trends continue to increase the value of property at risk and the potential cost of future catastrophes:
There is more property to insure. Property exposure in the countries Verisk models has grown roughly 7 percent annually since 2021, driven by both new construction and rising asset values. The cost of rebuilding keeps increasing. In the United States, residential reconstruction costs have risen about 5 percent annually since 2021, outpacing consumer inflation and increasing the potential cost of catastrophe losses even when hazard activity remains unchanged. More people and property are concentrated in hazard-prone areas. Population growth continues to be concentrated in catastrophe-exposed regions, while development expands in flood plains, wildfire zones and other high-risk locations. In England, for example, 7.1 percent of single-family homes already sit in the 100-year flood plain, and one in nine new homes built between 2022 and 2024 was built in a flood-risk area — a share Verisk’s models project could rise to one in seven new homes by 2050. Together, these trends increase insured catastrophe losses independently of weather patterns and help explain why the industry's risk benchmark continues to rise.
What would that mean in practice? Verisk's models show that adding a significant U.S. landfalling hurricane to a year like 2025 could push annual insured catastrophe losses to roughly $200 billion. Industry reports indicate that total insured losses for 2025 ranged from $107-$129 billion. The figure reflects an aggregate total across all perils in a single year, not a single mega-event. Verisk's report treats that figure as a foreseeable scenario the industry should be prepared to withstand, not a tail risk to revisit only after it happens. For consumers, a year with increased significant natural catastrophe events could mean increased premiums, changes to underwriting terms, and in the hardest-hit areas, less available coverage in subsequent years.
Why a quiet hurricane season is not a quiet year
Verisk's report underscores that a year without a U.S. landfalling hurricane can lull the market toward thinner pricing and looser underwriting terms, precisely when discipline matters most. Down years, the report notes, are when catastrophe models help insurers separate resilience from volatility when the market eventually turns.
“The $171 billion figure is not determined by the outcome of one hurricane season or one year of catastrophe losses,” said Dr. Jay Guin, executive vice president and chief research officer of Verisk Catastrophe and Risk Solutions. “It reflects a wide distribution of potential events across perils and regions, using current exposure data and a view of hazard grounded in the near-present climate. That broader perspective helps the industry prepare for loss scenarios that historical experience alone may not reveal.”
A persistent global protection gap
The report also quantifies a persistent and uneven protection gap. Globally, only about 38 percent of economic losses from natural catastrophes are insured, corresponding to a modeled economic AAL of more than $450 billion. In Europe, the gap is wider than the global average: of the region's $110 billion in expected annual economic catastrophe losses, only about $24 billion (22 percent) is currently insured. In July 2025, flash floods in Central Texas, the deadliest flood event in nearly five decades, occurred in a region where the national flood insurance take-up rate is about 3 percent, and take-up in the hardest-hit county was about 2.5 percent. When an earthquake struck Myanmar in March 2025, insurers covered less than $100 million of roughly $12 billion in economic losses.
“Narrowing the protection gap requires broader access to insurance and a clear understanding of the risk,” Newbold said. “By expanding model coverage and making both Verisk and third-party models available through our platforms, we are helping insurers evaluate risk in more markets and identify opportunities to extend coverage to communities that remain underinsured.”
About the report
The 2026 Global Modeled Catastrophe Losses Report is produced using the same suite of catastrophe models and software that Verisk's insurance and reinsurance clients rely on every day, covering more than 120 countries and regions, so its figures can be reproduced and tested in clients' own environments. The full report is available here.
Verisk’s catastrophe models are developed by AIR Worldwide Corporation, a wholly owned subsidiary of Verisk Analytics, Inc.
###
About Verisk
Verisk (Nasdaq: VRSK) is a leading strategic data analytics and technology partner to the global insurance industry. It empowers clients to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud and make informed decisions about global risks, including climate change, extreme events, sustainability and political issues. Through advanced data analytics, software, scientific research and deep industry knowledge, Verisk helps build global resilience for individuals, communities and businesses. With teams across more than 20 countries, Verisk consistently earns certification by Great Place to Work. For more, visit Verisk.com and the Verisk Newsroom.
Contribution to global insured AAL by peril for all regions
Contribution to global insured AAL by peril for all regions The AAL represents expected losses over extended periods, not what would be expected in any given ye...
Furuno uvede SOLION-100 pro Iridium GMDSS, který v jednom terminálu spojuje GMDSS, SSAS a LRIT pro nové i retrofitované lodě. Komerčně má být pro retrofit dostupný koncem roku 2026, u novostaveb má dostupnost následovat v roce 2027.
Furuno Unveils New SOLION-100 Terminal for Iridium GMDSS PR Newswire
HAMBURG, Germany, Sept. 1, 2026
The SOLION-100 combines GMDSS, Ship Security Alert System and Long-Range Identification and Tracking capabilities in a single Iridium Certus 100 terminal for newbuild and retrofit vessels.
, /PRNewswire/ -- Iridium Communications Inc. (Nasdaq: IRDM), a leading provider of global voice, data, aircraft surveillance, and positioning, navigation, and timing (PNT) satellite services, and Furuno Electric Co., Ltd. today announced Furuno will offer its new SOLION-100 terminal for Iridium GMDSS. This new Furuno maritime safety terminal is built on Iridium® Certus 100 technology and integrates GMDSS, Ship Security Alert System (SSAS) and Long-Range Identification and Tracking (LRIT) capabilities in a single platform.
Iridium GMDSS entered service in 2020 following recognition by the International Maritime Organization (IMO), becoming the first new provider of satellite GMDSS services since the system was established. It delivers regulated maritime distress and safety communications through Iridium's low-Earth orbit (LEO) satellite network, with global coverage, including the polar regions.
Furuno's addition of Iridium GMDSS to its portfolio gives shipowners and shipyards greater choice in selecting maritime safety equipment for newbuild and retrofit vessels.
"Furuno has been committed to supporting safer navigation at sea for decades, and maritime safety remains at the heart of what we do," said Kiyoshi Furuno, Head of Marine Electronic Products Division and Sales Management Department General Manager, Furuno. "The new SOLION-100 terminal for Iridium GMDSS allows us to strengthen our safety communications portfolio and provide customers with LEO satellite GMDSS technology alongside the Furuno navigation and communications systems they already rely on."
"Furuno has a long history of supporting maritime safety, and its addition of Iridium GMDSS brings together that expertise with the global coverage of the Iridium network," said Wouter Deknopper, vice president and general manager, maritime, Iridium. "Together, we are giving shipowners and shipyards another way to equip vessels with reliable maritime safety communications, including in the polar regions."
Iridium GMDSS is designed to support crews throughout a maritime safety event, from receiving navigational and meteorological warnings through Iridium SafetyCast® to initiating a distress alert and establishing Safety Voice communications with a Rescue Coordination Center. A single-button distress alert transmits the vessel's identification, status and position, while Safety Voice enables crews to communicate directly with rescue authorities to provide additional information about the situation.
The SOLION-100 is expected to be commercially available for retrofit applications in late 2026, with availability for newbuild projects expected to follow in 2027.
Iridium is exhibiting this week at SMM Hamburg. Visit booth Hall B6 Stand 313 to learn more about Iridium PNT, Iridium GMDSS, and other critical maritime safety services.
For more information about Iridium GMDSS, visit https://www.iridium.com/gmdss.
About Iridium Communications Inc.
Iridium Communications Inc. (Nasdaq: IRDM) operates the world's only truly global mobile satellite network. It serves as a platform for innovation, enabling voice, data, and messaging, positioning, navigation, and timing (PNT), and aircraft surveillance services anywhere on Earth. Through its satellite constellation and integrated capabilities like Aireon, the world's only space-based air traffic surveillance system, Iridium delivers services that support safety-focused operations across aviation, maritime, government, industrial, and consumer markets. The company is a leader in satellite Internet of Things (IoT) connectivity and is advancing direct-to-device (D2D) communications based on open standards to expand access to satellite services.
Headquartered in McLean, Virginia, Iridium innovates through an ecosystem of more than 500 technology and distribution partners, serving millions of customers worldwide. For more information visit www.iridium.com.
Press Contact:
Investor Contact:
Jordan Hassin
Kenneth Levy
Iridium Communications Inc.
Iridium Communications Inc.
[email protected]
[email protected]
+1 (703) 287-7421
+1 (703) 287-7570
View original content to download multimedia:https://www.prnewswire.com/news-releases/furuno-unveils-new-solion-100-terminal-for-iridium-gmdss-302865430.html
RapidFort oznámil integraci s CrowdStrike Falcon Cloud Security, která má urychlit nápravu zranitelností kontejnerů v prostředích Kubernetes. Řešení kombinuje data o zranitelnostech a SBOM s automatickým zpevňováním image.
Integration Helps Joint Customers Identify, Prioritize, and Remediate Container Vulnerabilities across Kubernetes Environments
LAS VEGAS--(BUSINESS WIRE)--Fal.Con 2026 – RapidFort today at Fal.Con 2026 announced a new integration with CrowdStrike Falcon® Cloud Security. The integration helps joint customers accelerate container vulnerability remediation across Kubernetes environments by combining the comprehensive cloud security capabilities of Falcon Cloud Security with RapidFort automated container image hardening.
New integration helps joint customers accelerate container vulnerability remediation across Kubernetes environments by combining the comprehensive cloud security capabilities of Falcon Cloud Security with RapidFort automated container image hardening.
ShareAs AI accelerates vulnerability discovery and shortens the window between CVE disclosure and potential exploitation, organizations running Kubernetes at scale face increasing pressure to address vulnerabilities faster. Containerized workloads can inherit vulnerabilities from open-source base images and packages, creating significant remediation demands across large environments.
The integration enables RapidFort to ingest vulnerability and software bill of materials (SBOM) data from Falcon Cloud Security and use it to automate container image hardening. RapidFort curated image library and runtime profiling capabilities help eliminate identified vulnerabilities and remove unnecessary components without requiring changes to application code. Together, CrowdStrike and RapidFort help joint customers streamline vulnerability management and accelerate risk reduction across Kubernetes environments.
“AI-accelerated vulnerability discovery has made speed increasingly critical for organizations running Kubernetes at scale,” said George Manuelian, CSO, RapidFort. “Our integration with CrowdStrike brings RapidFort automated image hardening into the vulnerability management workflow, helping joint customers move faster from identifying risk to reducing it. RapidFort customers have reduced CVEs by up to 99.9% with our hardening technology, without requiring changes to application code.”
For organizations with stringent security and compliance requirements, including Department of Defense environments, RapidFort supports hardened container images, compliance reporting, and deployment across restricted and air-gapped environments.
To learn more about the integration, visit the CrowdStrike Marketplace listing or visit RapidFort at ReversingLabs Booth #2113 during Fal.Con 2026 in Las Vegas this week.
About RapidFort
RapidFort leads the Software Supply Chain Security market with the largest distribution of curated, genuinely open-source software. Its platform enables organizations to eliminate risk at scale through hardened near-zero CVE container images, runtime profiling, attack surface management, and the industry’s first independently malware-scanned open-source images – cutting CVE exposure by up to 99.9% without code changes or platform migration. RapidFort is recognized in the inaugural Gartner® Magic Quadrant™ for Software Supply Chain Security, named a Gartner® Cool Vendor™, and honored as a Nutanix .Next Partner of the Year. The company is backed by Blue Cloud Ventures and Forgepoint Capital and headquartered in Sunnyvale, Calif. Visit www.RapidFort.com.
RapidFort, RAPIDFORT, and RBOM are registered trademarks of RapidFort, Inc. CrowdStrike and Falcon are registered trademarks of CrowdStrike, Inc. All other marks and names mentioned herein may be trademarks of their respective companies.
Photon Energy ukončila hlasování držitelů dluhopisů mimo zasedání, které vyhlásila 30. července 2026 v souvislosti s navrhovanou restrukturalizací svého zeleného dluhopisu 2021/2027 v objemu 78,77 mil. EUR s kuponem 6,50 % (ISIN DE000A3KWKY4). Ukončení nabývá účinnosti 1. září 2026. Podle firmy by návrhy v této podobě pravděpodobně neprošly a objevily se i procesní námitky.
Energetická skupina Photon Energy ukončila hlasování držitelů dluhopisů mimo zasedání, které vyhlásila 30. července 2026 v souvislosti s navrhovanou restrukturalizací svého zeleného dluhopisu 2021/2027 v objemu 78,77 mil. EUR s kuponem 6,50 % (ISIN DE000A3KWKY4). Ukončení nabývá účinnosti 1. září 2026.
Skupina uvádí dva důvody. Po zveřejnění výzvy obdržela od držitelů protinávrhy a žádosti o zařazení dalších bodů k hlasování a po jejich posouzení dospěla k závěru, že navrhovaná usnesení by v současné podobě pravděpodobně nezískala dostatečnou podporu. Dodatečné návrhy držitelů navíc podle společnosti otevírají otázky vyžadující další analýzu.
Druhým důvodem jsou procesní námitky. Jeden z držitelů zpochybnil, zda je hlasování mimo zasedání podle emisních podmínek vůbec odpovídajícím postupem. Emitent proto z opatrnosti od výzvy ustoupil, aby předešel nejistotě nebo pozdějšímu napadení hlasování či přijatých usnesení.
Photon Energy nyní protinávrhy, dodatečné body a vznesené procesní otázky vyhodnotí. Pokud shledá úpravy návrhů nebo postupu jako namístě, provede je ještě před zahájením dalšího rozhodovacího procesu držitelů. O novém jednání či hlasovacím postupu a případném revidovaném programu chce věřitele informovat bez zbytečného odkladu.
Akcie Photon Energy Akcie společnosti Photon Energy (BAAPEN) včera na pražské burze uzavřely na 7,4 Kč.
Revenues of $1.88 billion, approximately 6.3% growth; 5.3% organic growth(1)Net income of $102 million; Adjusted EBITDA(1) of $193 million or 10.3% of revenuesDiluted earnings per share of $2.38; Adjusted diluted earnings per share(1) of $3.01Cash flows provided by operating activities of $146 million; Free cash flow(1) of $131 millionNet bookings of $1.2 billion; quarterly book-to-bill ratio of 0.6; trailing twelve months book-to-bill ratio of 0.8Company increases fiscal year 2027 guidance for revenue, adjusted EBITDA(1), adjusted EBITDA margin %(1) and adjusted diluted EPS(1); reiterates free cash flow(1) guidance RESTON, Va., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Science Applications International Corporation (NASDAQ: SAIC), a premier mission integrator driving our nation's digital transformation across the defense, space, intelligence, and civilian markets, today announced results for the second quarter ended July 31, 2026.
"I am proud of our team’s performance this quarter, delivering solid organic growth and double-digit margins as we continue to execute with discipline," said Jim Reagan, SAIC Chief Executive Officer. "These results reflect our focus on operational excellence and our commitment to the targets we set for the year. We are raising our guidance to reflect our strong year-to-date performance, and we are transforming our enterprise to support our customers’ most critical missions, drive long-term growth and margin expansion, while continuing to invest in strengthening our capabilities."
Second Quarter of Fiscal Year 2027: Summary Operating Results
Three Months Ended July 31,
2026 Percent
change August 1,
2025 (dollars in millions, except per share amounts)Revenues$1,880 6%
$1,769 Operating income 152 9%
139 Operating income as a percentage of revenues 8.1% 20bps 7.9%Adjusted operating income(1) 191 5%
182 Adjusted operating income as a percentage of revenues 10.2% -10bps 10.3%Net income 102 (20)% 127 EBITDA(1) 193 9%
177 EBITDA as a percentage of revenues 10.3% 30bps 10.0%Adjusted EBITDA(1) 193 4%
185 Adjusted EBITDA as a percentage of revenues 10.3% -20bps 10.5%Diluted earnings per share$2.38 (12)% $2.71 Adjusted diluted earnings per share(1)$3.01 (17)% $3.63 Net cash provided by operating activities$146 20%
$122 Free cash flow(1)$131 (13)% $150 (1)Non-GAAP measure, see Schedule 6 for information about this measure.
Second Quarter Summary Results
Revenues for the quarter increased $111 million or approximately 6% compared to the same period in the prior year primarily due to ramp up in volume on existing and new contracts and from the acquisition of SilverEdge Government Solutions ("SilverEdge") of $20 million, partially offset by contract completions. Adjusting for the impact of acquisitions, revenues grew by approximately 5.3%.
Operating income as a percentage of revenues for the quarter increased compared to the same period in the prior year primarily due to improved profitability across our contract portfolio and costs related to the settlement of federal tax audits in the prior year, partially offset by higher selling, general and administrative expenses, including recovery of costs from the settlement of a patent infringement matter in the prior year.
Adjusted EBITDA(1) as a percentage of revenues for the quarter decreased to 10.3% from 10.5% for the same period in the prior year primarily due to higher selling, general and administrative expenses, including recovery of costs from the settlement of a patent infringement matter in the prior year, partially offset by improved profitability across our contract portfolio.
Diluted earnings per share for the quarter was $2.38 compared to $2.71 in the prior year quarter. Adjusted diluted earnings per share(1) for the quarter was $3.01 compared to $3.63 in the prior year quarter. The weighted-average diluted shares outstanding during the quarter decreased to 42.8 million from 46.8 million during the prior year quarter.
(1)Non-GAAP measure, see Schedule 6 for information about this measure.
Cash Generation and Capital Deployment
Cash flows provided by operating activities for the second quarter increased $24 million compared to the prior year quarter primarily due to lower cash outflows from the usage of the Master Accounts Receivable Purchase Agreement ("MARPA") Facility, lower cash incentive-based compensation payments, and other changes in working capital, partially offset by timing of customer collections.
During the quarter, SAIC deployed $106 million of capital, consisting of $90 million of plan share repurchases and $16 million in cash dividends.
Subsequent to quarter end, on August 14, 2026, SAIC amended the MARPA to increase the aggregate facility limit from $300 million to $400 million.
Quarterly Dividend Declared
Subsequent to quarter end, on August 27, 2026, the Company's Board of Directors declared a cash dividend of $0.37 per share of the Company's common stock payable on October 23, 2026 to stockholders of record on October 9, 2026. SAIC intends to continue paying dividends on a quarterly basis, although the declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements and other factors.
Backlog and Contract Awards
Net bookings for the quarter were approximately $1.2 billion which reflects a book-to-bill ratio of 0.6 and a trailing twelve months book-to-bill ratio of 0.8. SAIC’s estimated backlog at the end of the quarter was approximately $22.1 billion. Of the total backlog amount, approximately $3.8 billion was funded.
Notable New and Recompete Awards:
U.S. Space and Intelligence Community: During the quarter, SAIC was awarded a five-year (three-year base, plus two, one-year option periods) recompete contract of approximately $400 million supporting a U.S. Intelligence Agency. Under this contract, SAIC will provide advanced systems engineering, technical integration, and mission support services for ground-based Intelligence Community programs that ultimately deliver decisive national advantage.
U.S. Army: During the quarter, SAIC was awarded a five-year contract (three-year base, plus two, one-year option periods) of approximately $330 million supporting all branches of the Armed Services. Under this contract, SAIC will provide engineering and professional services supporting system-of-systems ("SoS"), systems engineering ("SE"), live/virtual/constructive ("LVC"), and associated M&S and multi-domain operations models, simulations, and analysis. The M&S area provides various types of system-of-systems modeling and simulation support development of and improvements of systems.
U.S. Navy: During the quarter, SAIC was awarded a five-year contract (one-year base, plus four, one-year option periods) of approximately $130 million supporting the U.S Navy. Under this contract, SAIC will provide support with acquisition, development, and operational testing of various airborne electronic warfare systems.
Notable Awards Subsequent to Period End (not included in current quarter bookings):
U.S. Department of Homeland Security: Subsequent to the end of the quarter, SAIC was awarded a five-year (one-year base, plus four, one-year option periods) recompete contract of approximately $740 million with the U.S. Department of Homeland Security, in its Civilian business group. Under this task order, SAIC will provide full-scale operations and maintenance support for Customs and Border Protection systems that are essential to assessing security risk from travelers and cargo entering our country.
U.S. Intelligence Community: Subsequent to the end of the quarter, SAIC was awarded a position on the estimated $14 billion Contract Operations for Missile Evaluation and Testing ("COMET") multiple-award, indefinite-delivery, indefinite-quantity ("IDIQ") contract with the Missile and Space Intelligence Center ("MSIC"). If awarded task orders, SAIC would provide expertise to develop, maintain, and enhance hardware, software, systems, and foundational military intelligence capabilities across five mission task areas. Backlog does not include estimates of revenues to be derived from multiple-award, IDIQ contracts, but rather we record backlog and bookings when task orders are awarded.
Fiscal Year 2027 Guidance
The table below summarizes fiscal year 2027 guidance and represents the Company's views as of August 31, 2026.
CURRENTPRIOR Fiscal YearFiscal Year 2027 Guidance2027 GuidanceRevenue$7.2B - $7.3B$7.0B - $7.2BOrganic Growth(1)(2%) - (0%)(4%) - (2%)Adjusted EBITDA(1)$750M - $755M$720M - $730MAdjusted EBITDA Margin %(1)10.3% - 10.5%10.1% - 10.3%Adjusted Diluted EPS(1)$10.65 - $10.75$9.90 - $10.10Free Cash Flow(1)>$600M>$600M (1)Non-GAAP measure, see Schedule 6 for information about this measure.
Webcast Information
SAIC management will discuss operations and financial results in an earnings conference call beginning at 10:00 a.m. Eastern time on August 31, 2026. The conference call will be webcast simultaneously to the public through a link on the Investor Relations section of the SAIC website (https://investors.saic.com/). We will be providing webcast access only – “dial-in” access is no longer available. Additionally, a supplemental presentation will be available to the public through links to the Investor Relations section of the SAIC website. After the call concludes, an on-demand audio replay of the webcast can be accessed on the Investor Relations website.
About SAIC
SAIC® is a premier mission integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, intelligence, and civilian markets includes secure high-end solutions in mission IT, enterprise IT, engineering services and professional services. We integrate emerging technology, rapidly and securely, into mission critical operations that modernize and enable critical national imperatives.
We are approximately 23,000 strong; driven by mission, united by purpose, and inspired by opportunities. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately $7.3 billion. For more information, visit saic.com. For ongoing news, please visit our newsroom.
The Company does not provide a reconciliation of forward-looking adjusted diluted EPS to GAAP diluted EPS, adjusted EBITDA margin to GAAP net income or free cash flow to GAAP net cash flows from operating activities due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because certain deductions for non-GAAP exclusions used to calculate net income and cash flows from operating activities may vary significantly based on actual events, the Company is not able to forecast GAAP diluted EPS, GAAP net income or GAAP net cash flows from operating activities with reasonable certainty. The variability of the above charges may have an unpredictable and potentially significant impact on our future GAAP financial results.
Forward-Looking Statements
Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at www.saic.com or on the SEC’s website at www.sec.gov. Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.
Schedule 1:
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
Three Months Ended Six Months Ended July 31,
2026 August 1,
2025 July 31,
2026 August 1,
2025 (in millions, except per share amounts)Revenues$1,880 $1,769 $3,786 $3,646Cost of revenues 1,641 1,554 3,298 3,222Selling, general and administrative expenses 87 75 170 164Other operating (income) expense — 1 (13) —Operating income 152 139 331 260Interest expense, net 33 31 66 61Other (income) expense, net — — 1 5Income before income taxes 119 108 264 194Income tax (expense) benefit (17) 19 (47) 1Net income$102 $127 $217 $195 Weighted-average number of shares outstanding: Basic 42.4 46.7 43.1 47.1Diluted 42.8 46.8 43.4 47.3Earnings per share: Basic$2.41 $2.72 $5.03 $4.14Diluted$2.38 $2.71 $5.00 $4.12 Schedule 2:
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
July 31,
2026 January 30,
2026 (in millions)ASSETS Current assets: Cash and cash equivalents$126 $182Receivables, net 996 853Prepaid expenses 129 122Other current assets 28 22Total current assets 1,279 1,179Goodwill 2,943 2,944Intangible assets, net 697 761Property, plant, and equipment, net 122 110Operating lease right of use assets 210 193Other assets 172 167Total assets$5,423 $5,354LIABILITIES AND EQUITY Current liabilities: Accounts payable$597 $500Accrued payroll and employee benefits 334 316Other accrued liabilities 98 147Debt, current portion 33 19Total current liabilities 1,062 982Debt, net of current portion 2,452 2,468Operating lease liabilities 220 198Deferred income taxes 147 104Other long-term liabilities 106 102Equity: Total stockholders' equity 1,436 1,500Total liabilities and stockholders' equity$5,423 $5,354 Schedule 3:
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended Six Months Ended July 31,
2026 August 1,
2025 July 31,
2026 August 1,
2025 (in millions)Cash flows from operating activities: Net income$102 $127 $217 $195 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 39 35 79 71 Stock-based compensation expense 15 10 28 25 Deferred income taxes 22 110 43 109 Gain on sales of investments — — (12) — Other (2) (1) (4) — Increase (decrease) resulting from changes in operating assets and liabilities: Receivables (34) 58 (143) 49 Prepaid expenses and other current assets (29) (113) (14) (107)Accounts payable and other accrued liabilities (25) (117) 60 (84)Accrued payroll and employee benefits 56 48 18 (3)Operating lease assets and liabilities, net (1) (2) (2) (4)Other assets and other long-term liabilities, net 3 (33) 3 (29)Net cash provided by operating activities 146 122 273 222 Cash flows from investing activities: Expenditures for property, plant, and equipment (15) (7) (24) (15)Contributions to investments (3) (1) (9) (7)Purchases of marketable securities (5) — (9) (4)Sales of marketable securities 6 1 11 4 Proceeds from sales of investments — — 15 — Other 2 — 2 — Net cash used in investing activities (15) (7) (14) (22)Cash flows from financing activities: Stock repurchased and retired or withheld for taxes on equity awards (98) (110) (286) (252)Dividend payments to stockholders (16) (17) (33) (36)Principal payments on borrowings (1) (546) (2) (1,235)Proceeds from borrowings — 557 — 1,307 Issuances of stock 5 6 10 12 Other (4) (4) (4) (4)Net cash used in financing activities (114) (114) (315) (208)Net increase (decrease) in cash, cash equivalents and restricted cash 17 1 (56) (8)Cash, cash equivalents and restricted cash at beginning of period 117 55 190 64 Cash, cash equivalents and restricted cash at end of period$134 $56 $134 $56 Schedule 4:
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
SEGMENT OPERATING RESULTS
(Unaudited)
Three Months Ended Six Months Ended July 31,
2026 August 1,
2025 July 31,
2026 August 1,
2025 (dollars in millions)Revenues Defense and Intelligence$1,449 $1,374 $2,915 $2,807 Civilian 431 395 871 839 Total revenues$1,880 $1,769 $3,786 $3,646 Adjusted operating income (loss) Defense and Intelligence$138 $124 $284 $239 Civilian 56 54 124 106 Corporate (3) 4 4 (5)Total adjusted operating income$191 $182 $412 $340 Adjusted operating margin Defense and Intelligence 9.5% 9.0% 9.7% 8.5%Civilian 13.0% 13.7% 14.2% 12.6%Total adjusted operating margin 10.2% 10.3% 10.9% 9.3% Second Quarter Defense and Intelligence Results
Revenues for the quarter increased $75 million or 5% compared to the same period in the prior year primarily due to ramp up in volume on existing and new contracts and from the acquisition of SilverEdge of $20 million, partially offset by contract completions.
Adjusted operating income as a percentage of revenues increased compared to the same period in the prior year primarily due to improved profitability across our contract portfolio.
Second Quarter Civilian Results
Revenues for the quarter increased $36 million or 9% compared to the same period in the prior year primarily due to ramp up in volume on existing and new contracts, partially offset by contract completions.
Adjusted operating income as a percentage of revenues decreased compared to the same period in the prior year primarily due to timing and volume mix in our contract portfolio.
Second Quarter Corporate Results
Adjusted operating loss was $3 million for the current quarter compared to an adjusted operating income of $4 million during the same period in the prior year primarily due to higher selling, general and administrative expenses, including recovery of costs from the settlement of a patent infringement matter in the prior year.
Schedule 5:
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
BACKLOG
(Unaudited)
The estimated value of our total backlog as of the dates presented was:
July 31, 2026 January 30, 2026 Defense and
IntelligenceCivilianTotal SAIC Defense and
IntelligenceCivilianTotal SAIC (in millions)Funded backlog$2,883$935$3,818 $2,511$1,061$3,572Negotiated unfunded backlog 15,250 3,068 18,318 15,869 3,181 19,050Total backlog$18,133$4,003$22,136 $18,380$4,242$22,622 Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts and task orders as work is performed and excludes contract awards which have been protested by competitors until the protest is resolved in our favor. SAIC segregates backlog into two categories, funded backlog and negotiated unfunded backlog. Funded backlog for contracts with government agencies primarily represents contracts for which funding is appropriated less revenues previously recognized on these contracts, and does not include the unfunded portion of contracts where funding is incrementally appropriated or authorized by the U.S. government and other customers even though the contract may call for performance over a number of years. Funded backlog for contracts with non-government agencies represents the estimated value of contracts which may cover multiple future years under which SAIC is obligated to perform, less revenues previously recognized on these contracts. Negotiated unfunded backlog represents the estimated future revenues to be earned from negotiated contracts for which funding has not been appropriated or authorized, and unexercised priced contract options. Negotiated unfunded backlog does not include any estimate of future potential task orders expected to be awarded under indefinite delivery, indefinite quantity (IDIQ), U.S. General Services Administration (GSA) schedules or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders.
Schedule 6:
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
This schedule describes the consolidated non-GAAP financial measures included in this earnings release. While we believe that these non-GAAP financial measures provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding our long-term financial performance, they should be considered as supplemental in nature and not as a substitute for financial information prepared in accordance with GAAP. Reconciliations, definitions, and how we believe these measures are useful to management and investors are provided below. Other companies may define similar measures differently.
Non-GAAP Definitions
Organic growth: Organic growth is a performance measure that excludes the impact of acquisitions and divestitures. Organic growth is calculated by taking consolidated revenues and excluding revenues from acquisitions and divestitures during the periods presented, when applicable.
Adjusted operating income: Adjusted operating income is a performance measure that primarily excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Adjusted operating income is calculated by taking operating income and excluding amortization of intangible assets, depreciation of property, plant, and equipment, acquisition, integration, restructuring, and impairment costs, and any other material non-recurring costs. Adjusted operating income excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition.
EBITDA and Adjusted EBITDA: EBITDA is a performance measure that is calculated by taking net income and excluding interest and loss on sale of receivables, provision for income taxes, and depreciation and amortization. Adjusted EBITDA is a performance measure that excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Adjusted EBITDA is calculated by taking EBITDA and excluding acquisition, integration, restructuring and impairment costs, and any other material non-recurring costs.
Adjusted Diluted Earnings Per Share: Adjusted diluted earnings per share is a performance measure that excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Adjusted diluted earnings per share excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition.
Free Cash Flow: Free cash flow is calculated by taking cash flows provided by operating activities less expenditures for property, plant, and equipment and less cash flows from our Master Accounts Receivable Purchasing Agreement ("MARPA") Facility for the sale of certain designated eligible U.S. government receivables. Under the MARPA Facility, the Company can sell eligible receivables up to a maximum amount of $300 million. We believe that free cash flow provides management and investors with useful information in assessing trends in our cash flows and in comparing them to other peer companies, many of whom present similar non-GAAP liquidity measures. This measure should not be considered as a measure of residual cash flow available for discretionary purposes.
Acquisition, integration, restructuring and impairment costs: Acquisition and integration costs represent costs incurred related to our acquisitions and subsequent integration with acquired businesses. Restructuring and impairment costs represent costs incurred related to internal reorganizations and initiatives (e.g., Project Orbit), facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation.
Recovery of acquisition, integration, restructuring and impairment costs: Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards.
Costs related to the settlement of federal tax audits: Costs related to the settlement of federal tax audits represent costs related to the IRS audit settlement for fiscal years 2016 through 2019.
Gain on divestitures, net of transaction costs: The gain on divestitures includes gains recognized related to divestitures, net of transaction costs.
We believe that these performance measures provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding our long-term financial performance.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
Adjusted Operating Income
Three Months Ended Six Months Ended July 31,
2026 August 1,
2025 July 31,
2026 August 1,
2025 (dollars in millions)Revenues$1,880 $1,769 $3,786 $3,646 Operating income$152 $139 $331 $260 Operating income as a percentage of revenues 8.1% 7.9% 8.7% 7.1%Depreciation of property, plant and equipment 7 6 15 13 Amortization of intangible assets 32 29 64 58 Acquisition, integration, restructuring and impairment costs 2 1 4 4 Recovery of acquisition, integration, restructuring and impairment costs (1) — (2) (2)Costs related to the settlement of federal tax audits — 7 1 7 Gain on divestitures, net of transaction costs (1) — (1) — Adjusted operating income(1)$191 $182 $412 $340 Adjusted operating income as a percentage of revenues 10.2% 10.3% 10.9% 9.3% (1)Non-GAAP measure, see above for definition.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
EBITDA and Adjusted EBITDA
Three Months Ended Six Months Ended July 31,
2026 August 1,
2025 July 31,
2026 August 1,
2025 (dollars in millions)Revenues$1,880 $1,769 $3,786 $3,646 Net income$102 $127 $217 $195 Interest expense, net and loss on sale of receivables 35 34 70 68 Income tax expense (benefit) 17 (19) 47 (1)Depreciation and amortization 39 35 79 71 EBITDA(1) 193 177 413 333 EBITDA as a percentage of revenues 10.3% 10.0% 10.9% 9.1%Acquisition, integration, restructuring and impairment costs 2 1 4 4 Recovery of acquisition, integration, restructuring and impairment costs (1) — (2) (2)Costs related to the settlement of federal tax audits — 7 1 7 Gain on divestitures, net of transaction costs (1) — (1) — Adjusted EBITDA(1)$193 $185 $415 $342 Adjusted EBITDA as a percentage of revenues 10.3% 10.5% 11.0% 9.4% (1)Non-GAAP measure, see above for definition.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
Adjusted Diluted Earnings Per Share
Three Months Ended July 31, 2026 (in millions, except per share amounts) As Reported Amortization of intangible assets Acquisition,
integration,
restructuring and
impairment costs Recovery of
acquisition,
integration,
restructuring and
impairment costs Gain on divestitures,
net of transaction
costs Non-GAAP results(1)Income before income taxes$119 $32 $2 $(1) $(1) $151 Income tax (expense) benefit (17) (5) — — — (22)Net income$102 $27 $2 $(1) $(1) $129 Diluted EPS$2.38 $0.63 $0.04 $(0.02) $(0.02) $3.01 Three Months Ended August 1, 2025 (in millions, except per share amounts) As Reported Amortization of intangible assets Acquisition, integration, restructuring and impairment costs Costs related to the settlement of federal tax audits Non-GAAP results(1)Income before income taxes$108 $29 $1 $7 $145Income tax (expense) benefit 19 6 — — 25Net income$127 $35 $1 $7 $170 Diluted EPS$2.71 $0.75 $0.02 $0.15 $3.63 (1)Non-GAAP measure, see above for definition.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
Adjusted Diluted Earnings Per Share
Six Months Ended July 31, 2026 (in millions, except per share amounts) As Reported Amortization of intangible assets Acquisition, integration, restructuring and impairment costs Recovery of acquisition, integration, restructuring and impairment costs Costs related to the settlement of federal tax audits Gain on divestitures, net of transaction costs Non-GAAP results(1)Income before income taxes$264 $64 $4 $(2) $1 $(1) $330 Income tax (expense) benefit (47) (12) — — — — (59)Net income$217 $52 $4 $(2) $1 $(1) $271 Diluted EPS$5.00 $1.20 $0.09 $(0.05) $0.02 $(0.02) $6.24 Six Months Ended August 1, 2025 (in millions, except per share amounts) As Reported Amortization of intangible assets Acquisition, integration, restructuring and impairment costs Recovery of acquisition, integration, restructuring and impairment costs Costs related to the settlement of federal tax audits Non-GAAP results(1)Income before income taxes$194 $58 $4 $(2) $7 $261Income tax (expense) benefit 1 — — — — 1Net income$195 $58 $4 $(2) $7 $262 Diluted EPS$4.12 $1.23 $0.08 $(0.04) $0.15 $5.54 (1)Non-GAAP measure, see above for definition.
Schedule 6 (continued):
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NON-GAAP FINANCIAL MEASURES
(Unaudited)
Free Cash Flow
Three Months Ended Six Months Ended July 31,
2026 August 1,
2025 July 31,
2026 August 1,
2025 (in millions)Net cash provided by operating activities$146 $122 $273 $222 Expenditures for property, plant, and equipment (15) (7) (24) (15)Cash used from (provided by) MARPA Facility — 35 — (101)Free cash flow(1)$131 $150 $249 $106 FY27 GuidanceNet cash provided by operating activities>$635MExpenditures for property, plant, and equipmentApproximately $35MFree cash flow(1)>$600M (1)Non-GAAP measure, see above for definition.
GitLab Inc. (NASDAQ:GTLB) will release its second quarter earnings report after the closing bell on Tuesday, Sept. 1.
Analysts expect the San Francisco, California-based company to report quarterly earnings of 18 cents per share, down from 24 cents per share in the year-ago period. The consensus estimate for GitLab’s quarterly revenue is $273.36 million. It reported $235.96 million last year, according to Benzinga Pro.
On June 10, GitLab expanded its partnership with Alphabet Inc.’s (NASDAQ:GOOGL) Google Cloud by launching a fully managed GitLab offering designed for enterprises with strict data sovereignty and compliance requirements.
Shares of GitLab rose 3.7% to close at $46.54 on Monday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Cantor Fitzgerald analyst Jonathan Ruykhaver maintained a Neutral rating and increased the price target from $35 to $50 on Aug. 31, 2026. This analyst has an accuracy rate of 74%. BTIG analyst Nick Altmann maintained a Buy rating and raised the price target from $36 to $52 on Aug. 31, 2026. This analyst has an accuracy rate of 65%. TD Cowen analyst Derrick Wood maintained a Hold rating and raised the price target from $29 to $42 on Aug. 27, 2026. This analyst has an accuracy rate of 71%. JP Morgan analyst Brian Essex maintained a Neutral rating and boosted the price target from $32 to $44 on Aug. 26, 2026. This analyst has an accuracy rate of 66%. Wells Fargo analyst Ryan Macwilliams maintained an Equal-Weight rating and boosted the price target from $26 to $40 on Aug. 25, 2026. This analyst has an accuracy rate of 67%. Trending
Considering buying GTLB stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Cerebras a Compute Nordic Finland oznámily nové AI datacentrum ve městě Mikkeli s kapacitou až 165 MW. Projekt je formalizován sérií servisních objednávek se sedmiletými smluvními podmínkami a odhadovanou regionální investicí 1,0–1,7 miliardy €.
Facility backed by seven-year contracted capacity agreement and estimated €1.0–1.7 billion in regional investment for local development and employment | Source: Cerebras Systems Inc.
MIKKELI, Finland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cerebras Systems (NASDAQ: CBRS) today announced a new AI data centre in Mikkeli, Finland, developed in partnership with Compute Nordic Finland. The facility will scale in phases to 165 MW of contracted IT capacity to deliver high-density AI compute with construction on the initial 50 MW phase already under way.
The agreement, formalized through a series of service orders each with seven-year contract terms, gives Cerebras long-term, purpose-built infrastructure to support growing global demand for its AI compute platform, while providing the Mikkeli region a long-term industrial anchor with significant estimated revenue and sustained job opportunities.
“This partnership with Cerebras is not a speculative bet on future demand — it's a contractually committed, phased build-out that reflects exactly how much AI compute the market needs today and where that need is heading,” said Pyry Virrantaus, CEO of Compute Nordic Finland. “We are proud to build that capacity in Mikkeli, alongside a partner network of local and national organizations who are ready to deliver the project and build the workforce it requires.”
More AI Per Megawatt
Cerebras and Compute Nordic designed the Mikkeli facility for efficiency from day one to optimize power and water usage. The facility is designed to use closed-loop cooling systems that recirculate water rather than draw continuously from municipal supply, and the campus is designed to support waste-heat recovery, enabling thermal energy generated by AI compute into a resource for the surrounding community.
“Our architecture is built to get more useful AI output out of every megawatt we deploy,” said Andrew Feldman, CEO and co-founder, Cerebras. “Mikkeli lets us pair that efficiency with a data centre designed for closed-loop cooling and heat reuse from the ground up.”
A Long-Term Industrial Anchor for South Savo
Cerebras' long-term commitment in Mikkeli reflects the company's broader approach to data centre development: building long-term technical capability and high-quality, permanent jobs around advanced AI infrastructure, rather than treating a site as a temporary construction project. As demand for Cerebras' wafer-scale AI compute continues to grow globally, Mikkeli adds a purpose-built, efficiency-first facility to the company's infrastructure footprint, with capacity scaling from 50 MW to 80 MW to a full 165 MW as data centre capacity is delivered.
Independent analysis from Ramboll's Finnish Data Center Market Study and Impact Assessment Report (12 September 2025) estimates that, at full 165 MW scale, the project represents an indicative investment of €1.0–1.7 billion for the region, supporting an estimated 80–250 direct permanent jobs and €0.8–2.5 million per year in property tax revenue.
Unlike the construction-heavy, short-lived employment sometimes associated with large data centre projects, Cerebras and Compute Nordic are emphasizing the permanent, technical roles the Mikkeli campus will create and sustain over the life of the facility — including operations, power and cooling engineering, networking, security, and facilities management — alongside the near-term construction and local supply chain activity already under way.
“The clearest measure of a project like this isn't the number of construction jobs it creates upfront; it's what remains ten or twenty years later,” Virrantaus said. “We looked at permanent employment, workforce pathways, local suppliers, and durable economic activity when building this out in Mikkeli.”
A Broad Partner Network
The Mikkeli project is developed in close cooperation with the City of Mikkeli and key regional stakeholders across South Savo, supported by a broad network of Finnish construction, engineering, energy, recruitment, and professional services partners.
Compute Nordic Finland is leading project development, operator responsibility, the customer interface, and overall programme governance.
About Cerebras Systems
Cerebras Systems (NASDAQ: CBRS) builds the world’s fastest AI infrastructure. The Cerebras team of pioneering computer architects, computer scientists, AI researchers, and engineers of all types came together to make AI blisteringly fast through innovation and invention. We believe that when AI is fast, it will change the world. Leading global corporations, research institutes, and governments choose Cerebras to run their AI workloads. Cerebras solutions are available on premises and in the cloud. Visit cerebras.ai for more.
About Compute Nordic Finland
Compute Nordic Finland develops and operates high-density AI data centre infrastructure in Finland, partnering with local communities, energy providers, and technology talent to deliver long-term industrial investment. Compute Nordic leads project development, operator responsibility, and programme governance for the Mikkeli AI Data Centre.
Cerebras Disclosure Information
Cerebras uses its blog (cerebras.ai/blog), investor relations page (investors.cerebras.ai), its X account (@cerebras), and its LinkedIn page (linkedin.com/company/cerebras-systems/) to disclose material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor these channels, in addition to following Cerebras press releases, Securities and Exchange Commission (SEC) filings, public conference calls and public webcasts.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of applicable securities laws. All statements other than statements of historical fact could be deemed to be forward-looking, including, but not limited to, statements about the partnership with Compute Nordic; expectations regarding contracted capacity and ability to deliver AI compute; impact on and direction of the AI infrastructure industry; long-term economic impact in Finland, including impact on employment, investment scale, and tax revenue; expectations regarding operational efficiency and environmental responsibility, including heat-reuse and closed-loop cooling; and any assumptions relating to the foregoing. The words "may," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "objective," or "continue," or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Cerebras’ control. These risks and uncertainties include, but are not limited to: Cerebras’ ability to sustain and manage its growth, access borrowings and other sources of capital on acceptable terms, and deploy available capital to support growth; its history of net losses and ability to achieve and maintain profitability; its limited operating history at its current scale and ability to accurately forecast revenue and appropriately budget and manage expenses; its dependence on a limited number of significant customers, including OpenAI, Group 42 Holding Ltd, Mohamed bin Zayed University of Artificial Intelligence, and AWS, and the potential impact of any reduction in demand from, material adverse development in its relationships with, or failure to meet its obligations to, such customers, including under its Master Relationship Agreement with OpenAI; the timing, execution and expected benefits of its strategic customer, partner and financing arrangements; its historical reliance on sales of hardware systems and the early-stage, rapidly evolving market for its cloud-based offerings and AI infrastructure; its ability to secure sufficient data center capacity and capital to support its cloud-based offerings; its ability to launch new offerings and add new product capabilities; and its ability to compete effectively in the rapidly evolving and competitive market for AI computing solutions.
Cerebras’ actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. Accordingly, undue reliance should not be placed on such statements. These forward-looking statements are made as of the date they were first issued and are based on information available to Cerebras together with Cerebras’ expectations, estimates, forecasts, projections, beliefs, and assumptions as of such date. These forward-looking statements should not be relied upon as representing Cerebras’ views as of any date subsequent to the date of this press release. Past performance is not necessarily indicative of future results. Cerebras undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Further information on potential risks that could affect actual results is included in Cerebras’ most recent filings with the SEC, including in Cerebras’ most recent Quarterly Report on Form 10-Q, copies of which may be obtained by visiting Cerebras’ Investor Relations website at investors.cerebras.ai or the SEC’s website at www.sec.gov.
Tesla uvedla v Hongkongu a Macau levnější Model 3, což poslalo akcie TSLA v pondělí o 3 % výše. Hongkongská cena je asi o 8,5 % pod předchozí základní nabídkou.
Tesla TSLA shares climbed 3% on Monday after the electric-vehicle maker introduced a lower-priced version of its Model 3 in Hong Kong and Macau.
The rear-wheel-drive model starts at HK$205,000 in Hong Kong, equivalent to about $26,000, and 252,000 patacas, or roughly $31,000, in Macau. The Hong Kong price is about 8.5% below Tesla's previous entry-level offering.
The lower-cost configuration gives Tesla another option for attracting buyers in two markets where affordability could influence demand. The move comes as EV manufacturers continue competing on price while regulators in the region tighten oversight of vehicle safety and technology.
Tesla and eight other automakers were also involved last month in a recall covering about 4.3 million vehicles in China over concerns that some doors could be difficult to open during emergencies. Beijing has raised safety requirements as competition among EV makers intensifies.
The cheaper Model 3 could help Tesla broaden demand, though pricing pressure and tighter regulatory scrutiny remain key factors for investors.
ARK Invest prodala AMD za zhruba 74,5 milionu USD, i když firma vykázala ve 2. čtvrtletí tržby 11,5 miliardy USD, meziročně o 50 % více. Tržby datových center se více než zdvojnásobily na 6,7 miliardy USD.
Cathie Wood Pulls $74 Million From AMD as Data Center Sales Soar Summary
Cathie Wood’s ARK Invest sold about $74 million of AMD shares even as the chipmaker delivered 50% revenue growth and a sharp rise in data-center sales
Advanced Micro Devices AMD is facing renewed investor scrutiny after Cathie Wood's ARK Invest reduced its position despite a sharp improvement in the chipmaker's latest results.
ARK sold 156,286 AMD shares valued at about $74.5 million across several ETFs. The transactions followed another disposal of 37,977 shares worth roughly $18.3 million a day earlier.
The sales come after AMD posted second-quarter revenue of $11.5 billion, up 50% year over year. Data Center revenue more than doubled to $6.7 billion, while non-GAAP earnings per share reached $1.66.
AMD also enters the second half with its data-center business as a major growth driver. The company said revenue from that segment is expected to accelerate, supported by EPYC processors and Instinct accelerators.
ARK's decision therefore contrasts with AMD's improving operating performance. It does not establish why the fund sold the shares, but it shifts attention toward whether AMD's strong AI-related growth can continue to justify its valuation.
The selling could weigh on sentiment, while accelerating data-center revenue remains an important support for the shares.
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
, /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company,"NYSE: XPEV and HKEX: 9868), a leading global Physical AI company, today announced its vehicle delivery results for August 2026.
XPENG delivered 39,107 vehicles in August 2026, up 4% year-over-year.
On August 11, 2026, the XPENG G9L made its official debut and commenced pre-sales in the Chinese mainland.
In August, XPENG Robotaxi business validation gained further progress. The Company secured a permit to conduct remote testing of intelligent connected vehicles in Guangzhou, allowing road trials without an onboard safety operator on designated Level 1, 2 and 3 test roads across the city and marking a key milestone toward fully driverless road testing.
XPENG's electric vehicles delivered from January to August 2026 are expected to reduce life-cycle greenhouse gas emissions by more than 3.72 million tons compared to internal combustion engine vehicles, equivalent to the carbon absorbed by 61.6 million young trees over 10 years.
About XPENG
XPENG is a leading global Physical AI company, dedicated to bringing artificial intelligence into the physical world to reshape future mobility and smart living. Through in-house R&D, XPENG has developed a full-stack Physical AI architecture spanning Turing AI chips, world foundation models, and highly integrated software and hardware applications. This unified technology foundation of XPENG powers an expansive product portfolio of smart EVs, robotaxis, and humanoid robots, advancing the deployment of Physical AI at scale. Headquartered in Guangzhou, China, XPENG is dual-primary listed on the New York Stock Exchange and the Hong Kong Stock Exchange. With global capabilities across R&D, manufacturing, sales, and services, XPENG drives continuous technological innovation and fosters an open Physical AI ecosystem, making life smarter, safer, and better for users worldwide. For more information, please visit https://www.xpeng.com/.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Statements that are not historical facts, including statements about XPENG's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: XPENG's goal and strategies; XPENG's expansion plans; XPENG's future business development, financial condition and results of operations; the trends in, and size of, China's EV market; XPENG's expectations regarding demand for, and market acceptance of, its products and services; XPENG's expectations regarding its relationships with customers, suppliers, third-party service providers, strategic partners and other stakeholders; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in XPENG's filings with the United States Securities and Exchange Commission. All information provided in this announcement is as of the date of this announcement, and XPENG does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Bernstein zvýšila cílovou cenu Affirm na 110 USD z 100 USD a ponechala doporučení Outperform, ale akcie během obchodování klesly o 6,12 %. Firma upozornila na růst počtu obchodníků o 51 % na 571 000 a na 5,2 milionu uživatelů Affirm Card.
Merchant count rose 51% to 571,000 as the Affirm Card reached 5.2 million users Summary
Bernstein lifted its target to $110 citing merchant and card growth, while the stock traded in the opposite direction.
Bernstein SocGen raised its price target on Affirm Holdings AFRM to $110 from $100, keeping an Outperform rating and pointing to network effects across merchants, the Affirm Card and newer verticals. The firm initiated coverage in July at $100. Affirm shares were down 6.12% intraday.
The raise follows fiscal fourth quarter results reported August 27. Revenue less transaction costs, Affirm's non-GAAP measure, came in 7% ahead of consensus, and adjusted operating income beat by 12%. Gross merchandise volume ran 5% above consensus on growth in both Pay in X products and interest-bearing loans. Fiscal 2027 guidance for revenue less transaction costs landed 4% above consensus, with adjusted operating income guidance in the teens above.
Merchant count rose 51% to 571,000, an acceleration of eight percentage points, and Affirm now works with 80 of the top 250 US merchants. The Affirm Card has 5.2 million users, with gross merchandise volume up 125% year over year. Bernstein said newer verticals are growing at two to three times the rate of the overall business, helped by independent software vendor partnerships.
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Dell ve výsledcích za druhé fiskální čtvrtletí 2027 ukáže, zda rostoucí ceny pamětí tlačí na marži jeho segmentu infrastruktury. Management už ceny opakovaně upravuje. Report přijde v úterý 1. září.
Dell Technologies (DELL -0.05%) reports its fiscal 2027 second-quarter results on Tuesday, Sept. 1, with a conference call set for 3:30 p.m. Central time. One line in that report interests me more than the revenue number, the earnings number, or the size of the artificial intelligence (AI) order backlog. It's the operating margin of Dell's infrastructure solutions group, the segment that builds the servers powering the AI build-out.
That's because memory prices have been climbing across the chip industry, and the companies that design AI chips have spent recent weeks describing what those costs are doing to their own margins.
Dell sits further down the same supply chain. It buys memory in huge volumes and assembles it into finished servers. If rising component costs are going to squeeze anyone's margins, the assembler is where the squeeze should show up first.
Tuesday's report gives investors their first good look at the answer.
Image source: Getty Images.
The margin already stepped down onceDell's infrastructure solutions group posted record first-quarter revenue of $29 billion, up 181% year over year. AI-optimized servers (machines built around graphics processing units and high-end memory) drove it, contributing $16.1 billion of revenue, nearly double the fiscal fourth quarter's $9 billion. And the company booked $24.4 billion of new AI server orders during the quarter. The rest of the segment grew, too -- traditional servers and networking revenue rose 92% year over year to $8.5 billion, while storage grew 8% to $4.3 billion.
The profitability was more complicated. Segment operating income was $3.1 billion, up 206% year over year, and the segment's operating margin of 10.5% was actually higher than the year-ago quarter's. However, it was down sharply from 14.8% in the fiscal fourth quarter.
Part of that step-down is seasonal. The segment's margin also fell sharply between the same two fiscal quarters a year earlier, from about 18% to under 10%, back when AI servers were less than a fifth of the segment. Much of the rest is mix, not memory. AI servers carry much thinner margins than Dell's traditional servers and storage, and chief financial officer David Kennedy said the AI server business is running in line with its target of a mid-single-digit operating margin.
In other words, when a low-margin product line grows from a sliver of the segment into more than half of it, the blended margin falls even if nothing is going wrong.
That's why Tuesday's number is so useful. The mix effect is known, and management has set the bar itself: Kennedy guided to a sequential improvement in the segment's operating margin this quarter. A margin that rises from the first quarter's 10.5% says Dell is passing its higher memory costs through. One that merely holds, or slips, says some of the bill is landing on Dell.
Management is already repricingDell hasn't been shy about naming the pressure. On the company's fiscal first-quarter earnings call in late May, chief operating officer Jeff Clarke described an inflationary environment across memory and other components, and said the company has been adjusting prices frequently in response.
Clarke also named notable commodity constraints, particularly in DRAM and NAND (the two main types of memory chips), as part of a challenging demand and supply environment.
The demand side looks fine. Dell guided second-quarter revenue to $44 billion to $45 billion, up about 50% at the midpoint. The infrastructure segment is expected to grow roughly 75%, including about $15.5 billion of AI server revenue. And adjusted earnings per share guidance of $4.80, plus or minus $0.10, implies growth of more than 100% year over year.
Growth, then, isn't in doubt on Tuesday. What the report settles is how much of it Dell keeps while one of its most important inputs gets more expensive by the quarter.
Premium Feature
Moneyball Superscore
86/100
Today's Change
(
-0.05
%) $
-0.23
Current Price
$
456.01
What would a good answer look like?I'd watch three things. First is the segment margin itself. A number above 10.5% says pricing power is holding, and one at or below it says it isn't. Second is the companywide gross margin, which fell to 17.8% in the first quarter from 21.1% a year earlier, largely on the AI mix. Another sharp drop there suggests costs are outrunning prices. And third is any updated commentary on memory, because Dell's guidance for the rest of the year assumes the repricing keeps working.
Shares trade near $461 as of this writing, at about 26 times the adjusted earnings management has guided to for this fiscal year -- arguably a full price for a hardware business, and one that assumes the AI growth stays profitable.
I think Dell probably passes the test. Management saw the memory problem early and started repricing months ago. But the margin line is the test, and the answer arrives Tuesday. I see no reason to guess a day early.
Australský soudce zvažuje, že v žalobě proti Tesle umožní nezávislému expertovi přístup k interním inženýrským platformám. Cílem je obejít vleklé spory o předávání dokumentů.
An Australian judge said he may order Tesla (TSLA.O) to give an independent expert access to its internal engineering platforms as part of a class action against the Elon Musk-led carmaker, a move designed to bypass a drawn-out discovery process that has dogged the case.
The lawsuit, filed in February 2025, alleges Tesla's Model 3 and Model Y vehicles suffer from "phantom braking" and that the advertised self-driving capability and battery range were overstated.
Federal Court judge Tom Thawley suggested appointing an independent expert after lawyers for the applicants, representing some 10,000 Tesla owners, complained the documents Tesla had turned over failed to capture crucial technical information they needed to run the case.
Bringing in an independent expert who was endorsed by both sides "would eliminate the discovery issue because they would have, if they needed access to something, the power to get access", Thawley told the court on Tuesday.
He added that he would not necessarily keep the court-appointed expert away from certain material "just because one of the parties doesn't like that idea".
The matter is yet to go to trial as the parties clash over the discovery process.
Tesla says it has handed over thousands of documents in good faith but that its engineers use live, continuously edited software platforms that do not keep point-in-time records or simulate paper documents.
Thawley said a single court-appointed expert in each relevant field with access to the systems themselves would be cheaper and faster than fighting over documents, and told the parties he would consider ordering it over their objections.
Lawyers for both sides said they would seek instructions on the suggestion of an independent expert, but Fiona Roughley, representing the applicants, said the idea made sense.
Imtiaz Ahmed, who represents Tesla, said his side would think about the suggestion, noting its systems were highly confidential.
Alphabet říká, že stále nestíhá budovat AI kapacitu, a Anthropic si zajistil zhruba 5 gigawattů nové TPU kapacity. Google Cloud mezitím ve 2. čtvrtletí zvýšil tržby o 82 % na 24,8 miliardy USD.
Alphabet (GOOG -2.18%)(GOOGL -2.09%) said something striking on its second-quarter earnings call in July. Even after committing to as much as $205 billion of capital spending this year, the company still can't build artificial intelligence (AI) computing capacity as fast as customers want it.
"[W]e continue to be supply constrained -- a sign of momentum and rapid adoption," CEO Sundar Pichai said in his remarks on the quarter.
Yet Alphabet has agreed to hand multi-gigawatt blocks of that scarce capacity to a fast-growing outside customer: Anthropic, the AI company behind the Claude models.
And a look at Alphabet's underlying business performance shows why the company is racing to sell its capacity to major customers like Anthropic -- even if it's scarce.
Image source: Alphabet Inc.
Selling scarce capacity is a great businessGoogle Cloud, the segment that sells cloud computing to outside customers, grew revenue 82% year over year to $24.8 billion in the second quarter. That was up from 63% growth in the first quarter.
The profit is growing even faster than the revenue. Google Cloud's operating income more than tripled year over year, from $2.8 billion to $8.8 billion -- after reaching $6.6 billion in the first quarter. The segment's operating margin came in at about 36%, versus about 21% in the year-ago quarter and 33% in the first quarter of this year.
And the contracted work keeps piling up. Pichai said cloud backlog (future revenue from signed contracts) grew to about $514 billion in the second quarter, up from $462 billion at the end of the first quarter. That backlog is now more than four times the revenue Alphabet's entire business produced last quarter.
How much of it is Anthropic?Alphabet doesn't break out the number, but the disclosed pieces -- even if they lack financial details -- are big. Last October, Anthropic agreed to expand its use of Google Cloud in a deal giving it access to up to 1 million of Google's tensor processing units (TPUs), the AI chips Google designs in-house, with well over a gigawatt of capacity coming online in 2026. Google Cloud said the agreement was worth tens of billions of dollars.
This spring, the relationship got much bigger. In early April, Anthropic secured multiple gigawatts of next-generation TPU capacity from Google and chip partner Broadcom, coming online starting in 2027 -- about 5 gigawatts in all, CNBC reported. Anthropic will access that capacity through Broadcom, according to a Broadcom securities filing. Weeks later, Google agreed to invest up to $40 billion in Anthropic itself, putting in $10 billion right away with as much as $30 billion more tied to performance milestones.
Worth noting from that Broadcom filing, though, is that Anthropic's use of the expanded capacity "is dependent on Anthropic's continued commercial success."
That is the honest risk in this arrangement.
To be fair, Anthropic said in April that its run rate revenue (its recent revenue pace, annualized) had surpassed $30 billion, up from about $9 billion at the end of 2025. Growth like that is extraordinary. But it means a meaningful slice of Alphabet's contracted future rests on one young AI developer growing into its commitments, and Alphabet is now an investor in that developer on top of being its supplier.
The build-out still has to be paid forOf course, Alphabet has to build all of this capacity before anyone can rent it. The company raised its 2026 capital expenditures guidance in July to $195 billion to $205 billion.
In the second quarter, capital spending of $44.9 billion exceeded the $39.1 billion of cash its operations produced. And the funding has gone well beyond cash on hand. Alphabet collected $49.6 billion from stock sales in June and issued senior notes (a form of debt) for another $20.3 billion of proceeds during the quarter.
In other words, the company is financing enormous capacity ahead of the revenue it will carry, and pre-selling chunks of it profitably.
Premium Feature
Moneyball Superscore
92/100
Today's Change
(
-2.09
%) $
-7.24
Current Price
$
339.35
What's in it for Alphabet? Probably more of the incredible momentum it's already seeing: Faster cloud revenue growth, a segment margin up from about 21% to about 36% in a year, and a $514 billion pile of signed contracts.
So, there's a lot to like here. The supply constraint Pichai described is another way of saying Alphabet has pricing power, and the Anthropic agreements convert that scarcity into contracted revenue years into the future -- something that should help an already thriving cloud business over the long haul.
And shares trade near $339 as of this writing, at about 23 times next year's expected earnings, which is arguably a reasonable price for a company growing total revenue by 24% (with an explosive cloud business underneath).
Chevron jedná o rozšíření ve Venezuele po dohodě, která má dát USA kontrolu nad více než 65 miliardami barelů tamních prokázaných zásob ropy. Firma už v zemi zajišťuje asi čtvrtinu produkce.
A few weeks ago, I wrote an article comparing the stocks of Chevron (CVX +2.12%) and ExxonMobil, saying I'd rather buy Chevron now. Given the events of the last week, I'm doubling down on that.
Last week, President Donald Trump announced a deal with Venezuela to give the U.S. control of more than 65 billion barrels of that country's proven oil reserves, which is about as much as the total proven reserves of the U.S. Venezuelan Interim President Delcy Rodriguez confirmed the 25-year agreement and said it would involve developing 17 oil fields and drawing more than $100 billion of investment.
Why is that good news for Chevron? The company appears to be intricately involved in the plan. News outlets are reporting that Chevron is now negotiating a major deal to expand operations in Venezuela.
Chevron has a big head start in Venezuela Chevron is the only American oil major that retained operations in Venezuela after the Bolivarian Revolution of 1999, which further nationalized the oil industry and forced many foreign oil companies out of the country. Today, Chevron's operations account for about one-fourth of Venezuelan oil production.
The opportunity for the company is massive. Venezuela has the largest proven crude oil reserves of any nation, about 303 billion barrels. That's even larger than Saudi Arabia's reserves. Basically, it sits on one-fifth of the world's oil.
And the company is on a bit of a roll. It reported net income of $12 billion for the second quarter, nearly 400% higher than the year-ago quarter. It beat Wall Street's earnings estimates by $0.50 a share, at $606.
Chevron is also a major refiner (as is ExxonMobil). Its refining profit soared from $737 million in the second quarter last year to $4.9 billion in the second quarter this year. Oil prices have been highly volatile this year, with increases driven by the Iran war boosting oil companies' revenues.
Image source: Getty Images.
While oil prices are expected to settle once the conflict ends, a global shortage of refining capacity will remain. That's a big positive for Chevron, which has the capacity to refine the heavy, sour crude that Venezuela produces. Chevron CEO Mike Wirth said in January that the company can process an additional 100,000 barrels per day of Venezuelan crude at its Pascagoula, Mississippi, refinery.
Premium Feature
Moneyball Superscore
68/100
Today's Change
(
2.12
%) $
4.28
Current Price
$
206.14
Shares of Chevron are up 35% year to date. And the average price target among analysts for CVX shares is $218.29, about 6.4% higher than the current price. Of the 25 analysts who follow the company, 20 rate it either a "strong buy" or a "buy."
Oracle má smluvní backlog 638 miliard USD, tedy víc než jeho tržní kapitalizace kolem 430 miliard USD. Zároveň ale backlog převádí na tržby pomalu a jeho obsluha vyžaduje vysoké kapitálové výdaje.
Here are two numbers that shouldn't normally sit next to each other. Oracle (ORCL -1.15%) ended fiscal 2026 with $638 billion of remaining performance obligations, which is contracted work its customers have signed up for that hasn't yet become revenue. The company's market value, meanwhile, is about $430 billion, with the stock near $150 as of this writing -- down about 57% from its high of $345.72.
In other words, Oracle's stock is worth roughly $200 billion less than the revenue its customers have already contracted to hand over. And even adding the company's roughly $98 billion of net debt to the price, the market values the whole business about $110 billion short of the backlog.
When Oracle revealed the $638 billion figure in June, alongside its fiscal 2026 fourth-quarter results (the fiscal year ended May 31), the company's market value stood near $580 billion. The stock has slid since, and the gap has only widened.
What is the market saying with a price like this? I think the answer comes down to two of Oracle's own disclosures. One is how slowly the backlog converts. The other is what serving it costs.
Image source: Getty Images.
A backlog that converts slowlyThe backlog itself is astonishing. Remaining performance obligations grew 363% year over year and rose $85 billion in the fiscal fourth quarter alone, driven by demand for cloud infrastructure to train and run artificial intelligence (AI) models.
And the revenue behind it is showing up: Oracle's cloud infrastructure revenue grew 55%, 68%, 84%, and then 93% year over year across fiscal 2026's four quarters. The business accelerated all year.
But contracted is not the same as soon. Management said on the June earnings call that it expects 12% of the backlog to be recognized as revenue over the next 12 months, and another 34% between 13 and 36 months. That works out to about $77 billion arriving within a year, and roughly $290 billion inside three years. More than half of the total sits further out than that.
For context, Oracle confirmed guidance for about $90 billion of total revenue in fiscal 2027, up from $67.4 billion in fiscal 2026, with fiscal first-quarter revenue expected to grow 27% to 29%. The backlog supports years of growth like that. It just can't be pulled forward.
Serving it costs real moneyThe second disclosure is what those contracts require. Oracle generated a record $32 billion of operating cash flow in fiscal 2026, up 54%. It spent all of that on data centers, and then some. Free cash flow came in at negative $23.7 billion.
So the company raised $43 billion in debt and $5 billion in equity during the fiscal year, and it expects to raise approximately $40 billion more in fiscal 2027 through a combination of debt and equity, including a previously announced $20 billion at-the-market stock program.
To the company's credit, its customers are helping carry the load. Oracle said the prepaid and customer-supplied hardware portions of its large AI contracts now total $75 billion, which "substantially reduces the amount of capital Oracle must raise to build out our AI datacenters."
Still, the shape of the business has changed. A company that used to throw off cash now consumes it. And each contracted dollar of AI infrastructure revenue arrives with heavy costs attached -- the graphics processing units, the buildings, and the electricity, plus the interest on the borrowing that funds them.
Premium Feature
Moneyball Superscore
75/100
Today's Change
(
-1.15
%) $
-1.73
Current Price
$
149.12
So is the stock cheap?A backlog bigger than the market cap sounds like an obvious bargain. It isn't, necessarily. Backlog is revenue, not profit, and the market's judgment is about what that revenue will be worth after Oracle pays for the infrastructure that produces it.
The stock trades at about 26 times earnings, and at about 19 times the $8.05 of adjusted earnings per share management has guided to for fiscal 2027. For a company guiding revenue up 34% this fiscal year, that isn't an expensive price. Arguably, it reflects doubt about the margins on AI contracts and about the years of heavy borrowing and stock sales still ahead.
Ultimately, I'd stay on the sidelines here. The contracted demand is enormous, but the economics of serving it are still being proven, and the balance sheet is absorbing tens of billions of dollars of strain in the meantime.
What nobody can see yet is how much profit all that contracted revenue leaves behind once the data centers are paid for. I'd want to see some of it first.
Apple v žalobě proti OpenAI tvrdí, že bývalý zaměstnanec Chang Liu použil důvěrné schéma čipu a pomáhal ničit důkazy. Firma žádá předběžné opatření, které by OpenAI dočasně zakázalo pracovat na hardwaru založeném na technologii Apple.
In its lawsuit against OpenAI, Apple filed what it calls “shocking evidence” to bolster its allegations that former employees stole trade secrets for OpenAI’s benefit. These new details emerged after the legal counsel for former Apple employee Chang Liu — who now works at OpenAI — handed over Liu’s old Apple work laptop for investigation earlier this month.
Apple now alleges that Liu used a confidential Apple circuit schematic in his work at OpenAI, as well as a tool that shares a name with an internal Apple engineering application. The company claims that OpenAI was “well-aware” of Liu’s access to Apple data, and that Liu enlisted OpenAI colleague Yu-Ting Peng to help destroy evidence in June when he learned that Apple was investigating him.
“The MacBook represents the very limited information Defendants provided so far (and only after weeks of delay), and shows Apple is not conducting ‘fishing expeditions’ but that its trade secrets are being used and evidence is being destroyed,” the filing reads.
While this new evidence is redacted from public view, past filings from Apple have included text messages from Liu — which he punctuated with “crying laughing” emojis — showing he was aware that he still had access to Apple files.
OpenAI has previously defended Liu by saying that he only accessed Apple files after he stopped working there in order to help former colleagues who asked for his assistance. “Apple now tries to shift the blame to ‘residual access,’ but they also don’t disclose that this is a common issue with Apple which is caused by them failing to properly manage system access when people leave,” OpenAI wrote in a blog post earlier this month.
But Apple claims that Liu had continued access because he “exploited a rare, previously unknown authentication bug.”
TechCrunch has requested comment from OpenAI on Apple’s newest allegations.
Apple is seeking a preliminary injunction — a court order that would block OpenAI from working on hardware based on Apple’s technology while the case is ongoing — as well as expedited discovery, a fast-tracked process for gathering evidence, since the company alleges that more former employees may also be implicated.
According to Apple’s initial filing, more than 400 former Apple employees now work at OpenAI.
Topics
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.
Amanda Silberling is a senior writer at TechCrunch covering the intersection of technology and culture. She has also written for publications like Polygon, MTV, the Kenyon Review, NPR, and Business Insider. She is the co-host of Wow If True, a podcast about internet culture, with science fiction author Isabel J. Kim. Prior to joining TechCrunch, she worked as a grassroots organizer, museum educator, and film festival coordinator. She holds a B.A. in English from the University of Pennsylvania and served as a Princeton in Asia Fellow in Laos.
You can contact or verify outreach from Amanda by emailing [email protected] or via encrypted message at @amanda.100 on Signal.
Motiva a Exxon Mobil připravují rafinerie v Port Arthuru a Beaumontu na silný vítr a možné záplavy, ale výrobu zatím neomezily. Exxon uvedl, že jeho rafinerie v Beaumontu a Baytownu pokračují v normálním provozu.
Motiva Enterprises and Exxon Mobil Corp (XOM.N) are preparing their East Texas refineries for high winds and possible flooding as a developing tropical storm nears the U.S. Gulf Coast, people familiar with plant operations said on Monday.
Motiva and Exxon have not reduced production at their Port Arthur and Beaumont, Texas refineries, respectively, but they have secured loose items and equipment that can be blown by high winds or drift in flood waters should those be produced by the developing storm expected to make landfall on Tuesday, the sources said.
Exxon spokesperson Kelly Davila said on Monday the company was monitoring the storm and both its Beaumont and Baytown, Texas, refineries continued to operate normally.
A Motiva spokesperson did not reply to a request for comment.
Cheniere Energy (LNG.N) and Freeport LNG said they were monitoring the storm. Cheniere added it would take steps to modify operations if necessary, but there had been no impact on production so far.
Cheniere operates liquefied natural gas plants at Sabine Pass on the Texas-Louisiana border and Corpus Christi, Texas.
Freeport LNG's plant is in Freeport, Texas.
The U.S. National Hurricane Center forecasts the storm, currently called Tropical Depression 5, to become Tropical Storm Edouard before making landfall near Port Arthur on Tuesday.
Edouard is not expected to reach hurricane strength and is forecast to produce winds no more than 58 miles per hour (93 kph), according to the hurricane center.
Exxon on Monday afternoon activated its Incident Command System, the sources said.
Valero Energy Corp (VLO.N) has not modified operations at its 235,000-barrel-per-day (bpd) Port Arthur refinery, sources at the refinery said.
The Motiva Port Arthur refinery is the nation's largest with a crude oil processing capacity of 656,400 bpd. Exxon's Beaumont refinery can intake 612,000 bpd while the Baytown refinery, on the east side of Houston, can process 564,000 bpd.
In the latest close session, Carnival (CCL - Free Report) was down 3.51% at $23.89. This change lagged the S&P 500's 0.33% loss on the day. Meanwhile, the Dow experienced a drop of 0.7%, and the technology-dominated Nasdaq saw a decrease of 0.12%.
The stock of cruise operator has fallen by 10.97% in the past month, lagging the Consumer Discretionary sector's gain of 2.03% and the S&P 500's gain of 3.87%.
The investment community will be paying close attention to the earnings performance of Carnival in its upcoming release. In that report, analysts expect Carnival to post earnings of $1.36 per share. This would mark a year-over-year decline of 4.9%. Alongside, our most recent consensus estimate is anticipating revenue of $8.36 billion, indicating a 2.59% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $2.23 per share and a revenue of $27.63 billion, demonstrating changes of -0.89% and +3.79%, respectively, from the preceding year.
Investors should also pay attention to any latest changes in analyst estimates for Carnival. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.02% higher. Right now, Carnival possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Carnival has a Forward P/E ratio of 11.1 right now. This expresses a discount compared to the average Forward P/E of 16.99 of its industry.
We can additionally observe that CCL currently boasts a PEG ratio of 1.03. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Leisure and Recreation Services industry had an average PEG ratio of 1.22 as trading concluded yesterday.
The Leisure and Recreation Services industry is part of the Consumer Discretionary sector. With its current Zacks Industry Rank of 176, this industry ranks in the bottom 29% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CCL in the coming trading sessions, be sure to utilize Zacks.com.
Oracle v poslední obchodní seanci oslabil o 1,15 % na 149,12 USD, což byl menší pokles než u indexu S&P 500, který ztratil 0,33 %. Trh vyhlíží výsledky, u nichž se očekává EPS 1,72 USD a tržby 19,14 miliardy USD.
Oracle (ORCL - Free Report) ended the recent trading session at $149.12, demonstrating a -1.15% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.33% for the day. Elsewhere, the Dow saw a downswing of 0.7%, while the tech-heavy Nasdaq depreciated by 0.12%.
Shares of the software maker witnessed a gain of 16.16% over the previous month, beating the performance of the Computer and Technology sector with its gain of 7.52%, and the S&P 500's gain of 3.87%.
Market participants will be closely following the financial results of Oracle in its upcoming release. The company is forecasted to report an EPS of $1.72, showcasing a 17.01% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $19.14 billion, indicating a 28.24% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.03 per share and a revenue of $89.8 billion, signifying shifts of +5.24% and +33.32%, respectively, from the last year.
Any recent changes to analyst estimates for Oracle should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.27% higher. Oracle is currently sporting a Zacks Rank of #2 (Buy).
Digging into valuation, Oracle currently has a Forward P/E ratio of 18.78. This indicates a premium in contrast to its industry's Forward P/E of 18.1.
We can additionally observe that ORCL currently boasts a PEG ratio of 0.76. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Computer - Software industry was having an average PEG ratio of 1.65.
The Computer - Software industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 96, placing it within the top 40% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Beacon Pointe Advisors LLC ve 2. čtvrtletí otevřela novou pozici v Intuit a koupila 6 280 akcií za zhruba 1,643 milionu USD. Intuit zároveň oznámil čtvrtletní dividendu 1,38 USD na akcii, vyšší než dříve 1,20 USD.
Beacon Pointe Advisors LLC bought a new position in Intuit Inc. (NASDAQ:INTU – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 6,280 shares of the software maker’s stock, valued at approximately $1,643,000.
A number of other large investors have also made changes to their positions in INTU. Betterment LLC boosted its stake in shares of Intuit by 2.1% during the 3rd quarter. Betterment LLC now owns 779 shares of the software maker’s stock worth $532,000 after purchasing an additional 16 shares during the last quarter. One Capital Management LLC lifted its position in Intuit by 2.7% during the third quarter. One Capital Management LLC now owns 681 shares of the software maker’s stock valued at $465,000 after buying an additional 18 shares in the last quarter. Quadcap Wealth Management LLC raised its stake in shares of Intuit by 1.0% during the third quarter. Quadcap Wealth Management LLC now owns 1,801 shares of the software maker’s stock valued at $1,230,000 after purchasing an additional 18 shares during the period. Washington Trust Bank raised its stake in shares of Intuit by 3.0% during the fourth quarter. Washington Trust Bank now owns 790 shares of the software maker’s stock valued at $523,000 after purchasing an additional 23 shares during the period. Finally, Barr E S & Co. increased its stake in shares of Intuit by 1.5% in the fourth quarter. Barr E S & Co. now owns 1,608 shares of the software maker’s stock worth $1,065,000 after buying an additional 24 shares during the last quarter. Hedge funds and other institutional investors own 83.66% of the company’s stock.
Intuit Stock Up 0.4% Shares of INTU traded up $1.45 on Monday, hitting $359.51. The company’s stock had a trading volume of 1,842,109 shares, compared to its average volume of 4,382,581. The firm has a market capitalization of $98.34 billion, a price-to-earnings ratio of 21.79, a P/E/G ratio of 0.92 and a beta of 0.97. The firm’s fifty day moving average price is $307.36 and its 200-day moving average price is $356.13. The company has a quick ratio of 1.45, a current ratio of 1.51 and a debt-to-equity ratio of 0.34. Intuit Inc. has a fifty-two week low of $252.84 and a fifty-two week high of $705.08.
Intuit (NASDAQ:INTU – Get Free Report) last issued its earnings results on Tuesday, August 25th. The software maker reported $4.03 earnings per share for the quarter, topping analysts’ consensus estimates of $3.58 by $0.45. Intuit had a net margin of 21.29% and a return on equity of 25.97%. The business had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.27 billion. During the same period in the previous year, the company earned $2.75 earnings per share. The firm’s revenue for the quarter was up 13.7% on a year-over-year basis. Intuit has set its Q1 2027 guidance at 2.440-2.480 EPS and its FY 2027 guidance at 22.880-23.120 EPS. On average, equities research analysts expect that Intuit Inc. will post 23.07 EPS for the current year. Intuit Increases Dividend The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Thursday, October 8th will be paid a dividend of $1.38 per share. The ex-dividend date is Thursday, October 8th. This is a positive change from Intuit’s previous quarterly dividend of $1.20. This represents a $5.52 dividend on an annualized basis and a yield of 1.5%. Intuit’s dividend payout ratio is currently 33.45%.
Key Stories Impacting Intuit Here are the key news stories impacting Intuit this week:
Positive Sentiment: Intuit announced a partnership with Perplexity to integrate QuickBooks and Mailchimp into Perplexity Computer, an agentic AI assistant. The collaboration could help users move from discovering information to receiving personalized insights and taking actions within Intuit’s software ecosystem. Intuit and Perplexity Team on AI Integrations Positive Sentiment: Recent AI-powered product enhancements for mid-market financial management support Intuit’s strategy of using automation and data-driven insights to expand the value of its QuickBooks platform. Intuit unveils AI-powered innovations for mid-market financial management Positive Sentiment: A comparison with PayPal argues that Intuit’s broad financial-software ecosystem, recurring customer relationships and AI investments provide a strong foundation for future growth. Intuit or PayPal: Which Fintech Is Built for Future Growth? Neutral Sentiment: Analyst commentary notes that INTU has significantly underperformed the Nasdaq over the past year, but expectations for its future remain cautiously positive. Other coverage highlights Intuit’s profitability and market leadership while comparing it with higher-risk AI software companies. Is Intuit Stock Underperforming the Nasdaq? Negative Sentiment: Several law firms publicized a securities class action and a September 8 lead-plaintiff deadline involving investors who purchased Intuit shares between February 25, 2025, and June 1, 2026. The notices cite a reassessment of TurboTax’s growth outlook and add legal and reputational uncertainty, although the allegations have not been proven. Intuit Inc. Securities Fraud Lawsuit Deadline Negative Sentiment: An Intuit executive sold 906 shares worth approximately $314,000, representing 36% of the executive’s direct holdings before the transaction. While the sale may be routine, its timing can weigh on sentiment amid the stock’s recent decline. An Intuit Executive Sells Over a Third of Their Direct Holdings Insider Transactions at Intuit In other news, CAO Lauren D. Hotz sold 907 shares of Intuit stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $346.54, for a total transaction of $314,311.78. Following the sale, the chief accounting officer directly owned 1,628 shares of the company’s stock, valued at approximately $564,167.12. This trade represents a 35.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Richard L. Dalzell sold 284 shares of Intuit stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $262.32, for a total value of $74,498.88. Following the completion of the transaction, the director directly owned 11,758 shares in the company, valued at approximately $3,084,358.56. This represents a 2.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,146 shares of company stock worth $662,666 over the last quarter. Corporate insiders own 2.49% of the company’s stock.
Wall Street Analysts Forecast Growth INTU has been the subject of several recent research reports. Mizuho lowered their target price on shares of Intuit from $500.00 to $430.00 and set an “outperform” rating for the company in a research note on Monday, August 17th. BNP Paribas Exane dropped their target price on shares of Intuit from $463.00 to $315.00 and set a “neutral” rating on the stock in a research report on Thursday, May 21st. JPMorgan Chase & Co. lowered Intuit from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $605.00 to $331.00 in a report on Wednesday, August 26th. Weiss Ratings downgraded Intuit from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 11th. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on Intuit from $530.00 to $425.00 and set a “buy” rating for the company in a research report on Wednesday, August 19th. Seventeen analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $434.68.
Check Out Our Latest Report on INTU
Intuit Company Profile (Free Report)
Intuit Inc (NASDAQ: INTU) is a financial software company headquartered in Mountain View, California, that develops and sells cloud-based financial management and compliance products for individuals, small businesses, self-employed workers and accounting professionals. Founded in 1983 by Scott Cook and Tom Proulx, the company has grown from desktop tax and accounting software into a diversified provider of online financial tools. As of my latest update, Sasan Goodarzi serves as Chief Executive Officer.
Intuit’s product portfolio includes QuickBooks, its flagship accounting and business-management platform that offers bookkeeping, payroll, payments and invoicing capabilities, and TurboTax, a tax-preparation and filing service aimed at individual taxpayers. In addition to these core offerings, Intuit has expanded through acquisitions to provide complementary services such as Credit Karma (consumer credit and financial-product marketplace) and Mailchimp (marketing and commerce tools), and it offers professional-grade tax solutions for accountants and tax preparers.
The company serves a mix of consumers, small and mid-sized businesses and accounting professionals across multiple markets, with a particularly large presence in the United States and an expanding international footprint.
Featured Stories Five stocks we like better than Intuit Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Intuit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuit and related companies with MarketBeat.com's FREE daily email newsletter.
Strategy po čtyřech prodejích znovu nakoupila Bitcoin za 370 milionů USD, a to za průměrnou cenu 80 318 USD za BTC. Firma tak dál drží přibližně 4 % celé nabídky Bitcoinu.
Strategy (MSTR +4.42%) is back to buying Bitcoin (BTC +1.29%).
On Aug. 31, the firm acquired $370 million of Bitcoin at an average purchase price of $80,318. The purchase came after four straight sales. In combination, these sales brought in roughly $430 million.
On paper, the moves appear confusing. Why dump $430 million in Bitcoin over a period of two months just to buy most of that stake back within weeks of the last sale?
The moves get even more confusing when you consider that Strategy executed its latest purchase at a higher price than its recent sales. Strategy's sales were executed at prices between $59,000 and $64,000 per Bitcoin. The latest purchase, however, was executed at roughly $80,000. The result was more than $80 million in sacrificed shareholder value when accounting for both the higher repurchase price and the foregone opportunity cost.
What exactly is Strategy's strategy here? The details of the situation may not be what you think.
Premium Feature
Moneyball Superscore
46/100
Today's Change
(
4.42
%) $
5.63
Current Price
$
132.94
Here's why Strategy is buying more BitcoinFor years, all Strategy did was add to its Bitcoin holdings. From its first purchase in the summer of 2020 all the way through late July of this year, the company never booked a net sale of the crypto asset. This summer, however, the firm booked four straight sales, only to buy back most of that stake on Aug. 31.
Crypto investors may naturally feel like the transactions reflect Strategy's stance on Bitcoin's valuation. But the truth is likely far less exciting.
Michael Saylor, the founder of Strategy, has long advised investors to "never" sell their Bitcoin. Earlier this year, however, Saylor floated the idea of selling some of the company's Bitcoin holdings.
"I said to you, 'Never sell your Bitcoin!' I never said that the company wouldn't sell its Bitcoin," he explained. "Strategy is a public company, not my wallet," he added, noting that he has never sold any of his personal Bitcoin holdings.
Why, then, did his company sell down its stake? The obvious reason is capital management. Strategy posted a $12.5 billion loss in the first quarter of 2026. The company also needed to fund a preferred dividend payment by June 30. Indeed, Strategy has been repurchasing its preferred shares at a discount to par in order to lower those obligations.
Image source: Getty Images
Saylor, of course, put a more positive spin on the sales.
"We'll probably sell some Bitcoin to fund a dividend just to inoculate the market, just to send the message that we did it. 'Look, the company's fine, the market's fine, the world didn't come to an end,'" he explained to investors. The sales, under this framework, were to be a sign of strength, not financial fragility or a reversal of its long-term Bitcoin thesis.
The truth is likely somewhere in between. Strategy has likely not lost faith in Bitcoin's long-term promise. But from a corporate management standpoint, it likely made sense to raise some extra cash, even if its management team wishes to downplay the need.
Regardless, Strategy still owns roughly 4% of all Bitcoin supply. The fact that the firm is buying again, and the fact that its period of selling did not trigger a market panic, are both positives for Bitcoin's long-term promise.
Kanadská léková agentura Canada’s Drug Agency (CDA-AMC) vydala konečné kladné doporučení pro veřejnou úhradu LEQEMBI od Eisai a Biogen u pacientů s mírným kognitivním poškozením nebo mírnou demencí kvůli Alzheimerově chorobě (časná AD). Dalším krokem jsou jednání přes pCPA a poté rozhodnutí veřejných plánů úhrad.
An Important Step Forward for Access to LEQEMBI® for Eligible Patients in Canada | Source: Biogen Inc.
TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of LEQEMBI® (lecanemab) for eligible patients in Canada living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (early AD).
The final recommendation follows a reconsideration by CDA-AMC and is an important step toward access to LEQEMBI. Next steps include negotiations through the pan-Canadian Pharmaceutical Alliance (pCPA), followed by individual reimbursement decisions by public drug plans in Canada’s provinces and territories.
More than 770,000 people in Canada were estimated to be living with dementia in 2025, and the number of people living with dementia in Canada is projected to increase to 1.7 million by 2050.¹
Eisai serves as the lead for lecanemab’s development and regulatory submissions globally, with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
MEDIA CONTACTS Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120
Biogen Inc.
Madeleine Shin
+1-781-464-3260 [email protected]
Eisai Europe, Ltd.
EMEA Communications Department
+44 (0) 7760 619251 [email protected] Eisai Inc. (U.S.)
Libby Holman
+1-201-753-1945 [email protected] INVESTOR CONTACTS Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122Biogen Inc.
Tim Power
+ 1-781-464-2442 [email protected] Notes to Editors
About lecanemab (generic name, brand name: LEQEMBI®)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab has been approved in 53 countries and regions including Japan, the U.S., China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 8 countries including the U.S., China, the UK, and others, and applications have been filed in 12 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. For subcutaneous initiation treatment (500 mg), approval was obtained in the United States in July 2026, and applications are under review in four countries, including Japan and China. In China, the application has been granted Priority Review designation. Since December 2025, lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List,” recently introduced by the National Healthcare Security Administration (NHSA) of China.
Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.
About Protofibrils
Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.2 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.3
About the Collaboration between Eisai and Biogen for AD
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.
About the Collaboration between Eisai and BioArctic for AD
Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.
About Eisai Co., Ltd.
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.
For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, including about the potential benefits, safety and efficacy of LEQEMBI (lecanemab); access to LEQEMBI for eligible patients in Canada; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.
These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.
These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.
References
Alzheimer Society of Canada. "Dementia numbers in Canada". Available at: https://alzheimer.ca/en/about-dementia/what-dementia/dementia-numbers-canada. Last accessed: August 20, 2026.Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-zOno K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.
Kalifornie a 11 dalších států vyzvaly soud, aby zamítl žádost Paramount Skydance o dluhopis za 1,88 miliardy USD kvůli zpoždění akvizice Warner Bros Discovery. Stát tvrdí, že škoda je vlastní vinou Paramountu.
The State of California and 11 other states joined the Writers Guild of America on Monday in urging a federal court judge to deny Paramount Skydance's (PSKY.O) request for a $1.88 billion bond to address the cost of delay in completing its acquisition of Warner Bros Discovery (WBD.O).
California argued that any damages Paramount has incurred from delays in closing the Warner Bros deal are self-imposed, a court filing on Monday showed. The state argued the studio willingly offered to pay Warner Bros shareholders a daily "ticking fee" for any delays in the merger as part of its effort to secure the deal.
Paramount also voluntarily agreed to refrain from closing the merger until the antitrust case is resolved, or June 1, 2027, whichever comes first.
"Paramount now wishes to offload its responsibility," California Attorney General Rob Bonta argued in the court filing, saying Paramount's request for a bond should be denied.
The company must pay a fee of $7 million a day if the $110 billion merger does not close by September 30. Paramount noted the trial on the states' legal challenge is scheduled for March and by the time it concludes and final legal briefs are submitted in April, it will have paid Warner Bros shareholders an unrecoverable $1.3 billion.
Hawaii Water Service požádala o úpravu sazeb v oblasti North Kona, aby pokryla investice do vodovodních a kanalizačních systémů. Pokud bude schválena, přinese asi 2,73 milionu USD ročních výnosů.
WAIKOLOA, Hawaii, Aug. 31, 2026 (GLOBE NEWSWIRE) -- California Water Service Group (Group) subsidiary Hawaii Water Service (Hawaii Water) has filed an application with the Hawaii Public Utilities Commission (HPUC) to recover costs for investments in the Kukio water and sewer systems and to serve its customers.
If approved as filed, the application would provide approximately $2.73 million in annual revenue to deliver safe, reliable water and wastewater service to Hawaii Water’s North Kona customers. The requested revenue would address system improvements and operating costs incurred since Hawaii Water’s last rate adjustment application was filed in 2019, as well as expected costs through 2027, including almost $1.66 million for the water system and nearly $1.07 million for the sewer system.
Specifically, the revenue sought by Hawaii Water is expected to help fund the recovery of about $5.53 million in water system improvements and $2.76 million in sewer system projects that have been completed since the last application was filed, some of which include:
Reverse-osmosis treatment plant controller upgrade and membrane replacements essential to continuing to meet water quality standards.New pressure-reducing valve station to help regulate water pressure.Upgrade of the Supervisory Control and Data Acquisition (SCADA) radio networks that support 24/7 remote-monitoring of the water and wastewater systems.A significant number of aging pump, motor, and valve replacements to help keep the systems functioning properly.Sewer pump station pump replacements, control upgrades, and discharge piping replacements to maintain system reliability.Replacement of a gravity sewer main to prevent leaks and operational concerns. An additional $7.92 million in water system projects and $14.93 million in sewer system projects are planned for completion by 2027 and included in the request, such as:
Rehabilitation and upgrade of a critical well and pumping facilities to expand water supply reliability.Replacement of aging valves to improve water system reliability and control.Installation, repair, and replacement of emergency backup power generators to help maintain water pressure during power interruptions and improve fire protection.Significant improvements to upgrade the Kukio Wastewater Treatment Plant to a moving-bed bioreactor process and install a necessary effluent disposal facility. “We are focused on providing safe, reliable, high-quality water and wastewater services to our Kona-area customers while operating in an efficient and environmentally responsible manner,” said Martin A. Kropelnicki, Group Chairman and CEO. “These investments support that commitment and help us continue to deliver quality, service, and value to our customers and community long-term.”
The HPUC will review and analyze Hawaii Water’s application, operations, investments, finances, and service prior to issuing a decision and setting Hawaii Water’s new rates. Hawaii Water delayed filing for rate adjustments, as its last application in 2019 did not result in an effective decision until 2023 due to pandemic-related delays. Any rate changes from this application could become effective in mid-2027.
About California Water Service Group
California Water Service Group (NYSE: CWT) is the largest regulated water utility in the western United States. It provides high-quality, reliable water and/or wastewater services to more than 2.2 million people in California, Hawaii, New Mexico, Washington, and Texas through its regulated subsidiaries, California Water Service, Hawaii Water Service, New Mexico Water Service, and Washington Water Service, and its utility holding company, TWSC, Inc. (Texas Water Service). This year, the company commemorates a century of service.
Group’s purpose is to enhance the quality of life for customers, communities, employees, and stockholders. To do so, it invests responsibly in water and wastewater infrastructure, sustainability initiatives, and community well-being. The company’s nearly 1,300 employees live by a set of strong core values and share a commitment to protecting the planet, caring for people, and operating with the utmost integrity. The company has been named one of “America’s Most Responsible Companies” and the “World’s Most Trustworthy Companies” by Newsweek, a USA Top Workplace, and a Great Place to Work®. More information is available at www.calwatergroup.com.
This news release contains forward-looking statements within the meaning established by the Private Securities Litigation Reform Act of 1995 (PSLRA). The forward-looking statements are intended to qualify under provisions of the federal securities laws for "safe harbor" treatment established by the PSLRA. Forward-looking statements in this news release are based on currently available information, expectations, estimates, assumptions and projections, and our management's beliefs, assumptions, judgments and expectations about us, the water utility industry and general economic conditions. These statements are not statements of historical fact. When used in our documents, statements that are not historical in nature, including words like will, would, expects, intends, plans, believes, may, could, estimates, assumes, anticipates, projects, progress, predicts, hopes, targets, forecasts, should, seeks or variations of these words or similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this news release include, but are not limited to, statements describing Hawaii Water's request to increase water and sewer rates and, if approved, the potential timing for such rates to become effective and plans for related cash receipts. Forward-looking statements are not guarantees of future performance. They are based on numerous assumptions that we believe are reasonable, but they are open to a wide range of uncertainties and business risks. Consequently, actual results or outcomes may vary materially from what is contained in a forward-looking statement. Factors that may cause actual results or outcomes to be different than those expected or anticipated include, but are not limited to those described under the section entitled "Risk Factors" and elsewhere in our most recent Annual Report on Form 10-K, our subsequent Quarterly Reports on Form 10-Q and our other Securities and Exchange Commission filings. In light of these risks, uncertainties and assumptions, investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. We are not under any obligation, and we expressly disclaim any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.
Parsons byla vybrána k účasti v novém pilotním programu Project Watershed 250 na ochranu kritické vodní infrastruktury. Firma uvedla, že nabídne kybernetické služby pro vodní sektor včetně red teamingu, posouzení zranitelností, remediation and mitigation a AI-enabled cyber defense.
Today Parsons joined national leaders at the Project Watershed 250 launch in San Antonio, Texas. This scalable water cybersecurity pilot program was initiated by White House National Cyber Director Sean Cairncross and Texas Governor Greg Abbott, with support from Parsons’ CEO Carey Smith and other industry leaders.Uniquely positioned at the convergence of national security and critical infrastructure, Parsons brings deep operational understanding of the water, utilities, transportation, health care, and facilities sectors, as well as the cybersecurity capabilities to protect them.Parsons’ unmatched ability to integrate engineering, operational technology, and cyber capabilities continues to drive project wins across our nation's most complex and mission-critical infrastructure programs. CHANTILLY, Va., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that it has been selected to participate in a new pilot program launched by the Trump Administration to protect critical water infrastructure which is vital to our society. Parsons’ Chair, President, and Chief Executive Officer, Carey Smith, joined national leaders in San Antonio, Texas, for the unveiling of Project Watershed 250.
“Project Watershed 250 comes at a pivotal moment, as critical infrastructure faces escalating and increasingly complex threats from AI-enabled cyberattacks, nation-state pre-positioning, and aging legacy systems,” said Smith. “For more than eight decades, Parsons has designed and developed global water infrastructure solutions, and we currently support more than 400 electric and water utilities across the United States.”
Smith continued: “Our experts serve as trusted cybersecurity partners to the nation’s intelligence community, defense, and critical infrastructure customers, and we look forward to offering extensive cybersecurity capabilities for this water sector pilot, including red teaming, vulnerability assessments, remediation and mitigation, and AI-enabled cyber defense. Parsons Corporation is honored to participate in this water sector cybersecurity pilot, and we have the experience, technical depth, and resources to support the full scope of this important initiative.”
A Leader in Cybersecurity, Technology and Infrastructure
Parsons brings more than 80 years of experience designing, building, and securing water and wastewater infrastructure, with deep expertise in programmable logic controllers, supervisory control and data acquisition (SCADA) networks, valves, pump stations, and water treatment plants. By integrating program management, engineering expertise, operational technology knowledge, critical information technology systems support, and rapid access to cyber threat intelligence, Parsons will help strengthen the pilot’s defense and resiliency and enable participating water utilities to stay ahead of evolving threats through proven, best-in-class cybersecurity capabilities. Parsons is proud to continue their more than 60 years of support to the state of Texas, in projects spanning transportation, water, and cyber.
In addition to the Watershed pilot, Parsons’ cybersecurity capabilities continue to grow through a portfolio of contract wins which highlight both our technical leadership and ability to deliver resilient solutions at scale.
Los Angeles World Airports (LAWA): Cybersecurity Consulting Services
Parsons played a key role in supporting LAWA with transformative technologies to strengthen its cybersecurity framework.Our team provides independent reviews, formal assessments, and compliance services aligned with industry standards and local, state, and federal regulations.Capabilities include vulnerability management, cyber audits, identity and access management, and identity governance and administration. Hudson Tunnel Project Design & Construction: Cybersecurity Expertise and Strategy
Parsons supports the design and building of the $16 billion Hudson Tunnel Project to create a new rail link between New Jersey and New York and repair the existing century-old tunnel.The company’s cybersecurity team acts as the virtual chief information security officer for the project. Dallas Fort Worth International Airport and Dallas Love Field Airport: AI, Innovation and Digital Modernization
Major transportation operators trust Parsons for technology transformation programs, including AI and innovation at Dallas Fort Worth International Airport and digital modernization at Dallas Love Field Airport.These engagements reflect Parsons' expertise in modernizing critical infrastructure through a secure-by-design approach that balances innovation, operational resilience, and cybersecurity considerations. Golden Gate Bridge Highway and Transportation District: On-Call Cybersecurity Professional Services
Parsons was selected in 2026 by The Golden Gate Bridge, Highway and Transportation District for an on-call contract for professional services related to all cybersecurity areas. To learn more about Parsons’ Critical Infrastructure capabilities, visit https://www.parsons.com/securing-critical-infrastructure/.
About Parsons:
Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact.
Forward-Looking Statements:
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs and assumptions, and are not guarantees of future performance. Forward-looking statements are inherently subject to uncertainties, risks, changes in circumstances, trends and factors that are difficult to predict, many of which are outside of our control. Accordingly, actual performance, results and events may vary materially from those indicated in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future performance, results or events. Numerous factors could cause actual future performance, results and events to differ materially from those indicated in the forward-looking statements, including, among others: any issue that compromises our relationships with the U.S. federal government or its agencies or other state, local or foreign governments or agencies; any issues that damage our professional reputation; changes in governmental priorities that shift expenditures away from agencies or programs that we support; our dependence on long-term government contracts, which are subject to the government’s budgetary approval process; the size of our addressable markets and the amount of government spending on private contractors; failure by us or our employees to obtain and maintain necessary security clearances or certifications; failure to comply with numerous laws and regulations; changes in government procurement, contract or other practices or the adoption by governments of new laws, rules, regulations and programs in a manner adverse to us; the termination or nonrenewal of our government contracts, particularly our contracts with the U.S. federal government; our ability to compete effectively in the competitive bidding process and delays, contract terminations or cancellations caused by competitors’ protests of major contract awards received by us; our ability to generate revenue under certain of our contracts; any inability to attract, train or retain employees with the requisite skills, experience and security clearances; the loss of members of senior management or failure to develop new leaders; misconduct or other improper activities from our employees or subcontractors; our ability to realize the full value of our backlog and the timing of our receipt of revenue under contracts included in backlog; changes in the mix of our contracts and our ability to accurately estimate or otherwise recover expenses, time and resources for our contracts; changes in estimates used in recognizing revenue; internal system or service failures and security breaches; and inherent uncertainties and potential adverse developments in legal proceedings, including litigation, audits, reviews and investigations, which may result in materially adverse judgments, settlements or other unfavorable outcomes. These factors are not exhaustive and additional factors could adversely affect our business and financial performance. For a discussion of additional factors that could materially adversely affect our business and financial performance, see the factors included under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the Securities and Exchange Commission. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. We assume no obligation to update any forward-looking statement made in this press release that becomes untrue because of subsequent events, new information or otherwise, except to the extent we are required to do so by law.
Investor Relations Contact:
Dave Spille
+1 703.775.6191 [email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f1595697-e7a4-405c-b2a8-ed69f1835581
A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ba9a6da8-cccd-49ac-bd9a-35b8eb1d5f9c
Project Watershed 250 Parsons' Chair, President, and CEO Carey Smith joins Texas Governor Greg Abbott and other national l... Advanced Critical Infrastructure Protection Critical infrastructure protection counters evolving threats to people, facilities, and vital system...
